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(57) ABSTRACT
Disclosed are microcapsules comprising a polymer shell
enclosing one or more immiscible liquid phases in which a
drug or drug precursor are contained in a liquid phase. The
microparticles also contain magnetic particles that can be
heated by application of an external magnetic field and thus
heated to a predetermined Curie temperature. Heating of the
particles melts the polymer shell and releases the drug with-
out causing heating of surrounding tissues.
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EXTERNALLY TRIGGERED
MICROCAPSULES
CLAIM OF BENEFIT OF PRIORITY OF
PRIOR-FILED CO-PENDING
NON-PROVISIONAL APPLICATION
This application is a divisional of commonly-owned U.S.
patent application Ser. No. 09/079,758, filed May 15, 1998
now abandoned.
CROSS-REFERENCE TO RELATED
APPLICATIONS
This applicationis a division of U.S. patent application Ser.
No. 09/079,758, filed May 15, 1998, now abandoned which is
a continuation-in-part of U.S. patent application Ser. No.
08/349,169 filed Dec. 2, 1994 (now U.S. Pat. No. 5,827,531);
and this application is related to the following U.S. Patent
Applications which are filed contemporaneously herewith:
(1) application Ser. No. 09/079,741 entitled "In situ Acti-
vation of Microcapsules" invented by Dennis R. Morrison
and Benjamin Mosier;
(2) application Ser. No. 09/079,833 entitled "Microencap-
sulation and Electrostatic Processing Device" invented by
Dennis R. Morrison, Benjamin Mosier and John M. Cassanto;
(3) application Ser. No. 09/079,770 entitled "Low Shear
Microencapsulation and Electrostatic Coating Process"
invented by Dennis R. Morrison and Benjamin Mosier;
(4) application Ser. No. 09/079,766 entitled "Microencap-
sulated BioactiveAgents and Method of Making" invented by
Dennis R. Morrison and Benjamin Mosier.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT
The invention described herein was made in the perfor-
mance of work under a NASA contract and is subject to the
provisions of Section 305 of the National Aeronautics and
Space Act of 1958, Public Law 85-568 (72 Star. 435; 42
U.S.C. 2457).
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to microcapsules, methods for mak-
ing microcapsules, encapsulating pharmaceutical com-
pounds in microcapsules, microcapsule encapsulated phar-
maceutical compositions and products, and methods of using
these compositions. The invention also relates to controlled
delivery of a substance contained in a microcapsule through
the use of magnetic particles that are heated upon exposure to
an electromagnetic field.
2. Description of the Related Art
Although encapsulation of a drug in a microcapsule or
other carrier addresses several problems of drug delivery, an
area of interest in the art of drug delivery is still the specific,
controlled release of the drug from the microcapsule when it
reaches the target site. Several approaches have been
described to solve this problem, including heating liposomes
to the melting temperature of the phospholipid bilayer by
inducing local hyperthermia or by heating magnetic powders
incorporated into the membranes, and also including physi-
cally shaking microcapsules by ultrasound or by oscillating
magnetic fields. However, the inventors are aware of no pre-
2
vious method in which a permanent hole is melted in a micro-
capsule comprising a polymer outer shell, so that the contents
are released through the pore.
In a controlled delivery system described by Supersaxo et
5 al. in U.S. Pat. No. 5,470,582, microparticles are made from
polymers such as polyesters, polyamides, polyanhydrides
and polyacrylates with pre-formed pores and an active agent
is allowed to migrate into the microparticles through the
pores. After administration, the active agent is released
io through the pores by diffusion. A burst of release may be
caused by application of ultrasonic radiation. Another sys-
tem, described by Mathiowitz et al. in U.S. Pat. No. 4,898,
734, is also based on passive or facilitated diffusion of an
active agent from pore-containing polymer microspheres.
15 Methods of facilitating diffusion include exposure to high
temperature, light, or ultrasound. This patent also describes
degradable microspheres and microspheres immobilized in a
polymer matrix. A controlled release delivery system
described by Modi in U.S. Pat. No. 5,417,982 is biodegrad-
2o able copolymer based microspheres in which delayed release
of an active agent is controlled by the time required for
enzymatic digestion of the polymer matrix. Wheatley et al., in
U.S. Pat. No. 4,933,185, describe microcapsules having an
inner core and an outer, ionic skin. An active agent and an
25 enzyme are encapsulated in the inner core, such that the
enzyme degrades the inner core and releases the active agent.
Controlled release of drugs from liposomes has been
achieved by using temperature sensitive polymers in the for-
mation of the liposomes (Magin et al. 1986). Once the lipo-
30 somes are localized in the target tissue (or tumor) the drug can
be rapidly released if the local tissue temperature can be
raised above the transition temperature of the liposome mem-
brane. This requires some method of controlled tissue heating
which is difficult to achieve without complicated surgical
35 procedures, implanted interstitial antennas or ultrasonics to
produce effective local hyperthermia (Hand, 1991). Ther-
mosensitive liposomes have been prepared from a variety of
natural and synthetic lipids such as dipalmitoyl phosphatidyl-
choline, distearoyl phosphatidylcholine, and cholesterol to
4o have transition temperatures of 41-43° C. so that the outer
phospholipid membrane melts and releases contained drugs
in response to local hyperthermia. Attempts have been made
to use these liposomes and local tissue hyperthermia for
achieving drug targeting to tumors.
45 Chelvi and Rathan (1995) prepared temperature-sensitive
liposomes from natural lipids, egg phosphatidylcholine:cho-
lesterol (PC:Ch) in a 7:1 molar ratio and ethanol, 6% (v/v)
having a transition temperature of 43° C. Fluorescence
labeled calcein was encapsulated in the liposomes and admin-
5o istered to mice, a group of whose tumor-bearing legs were
immersed in a water bath to achieve a tumor temperature of
43° C. and held there for one hour. Fluorescence microscopy
demonstrated the release of calcein from the temperature
sensitive liposomes. The in vivo efficacy of temperature-
55 sensitive unilamellar vesicles containing dacarbazine in com-
bination with hyperthermia was detected in murine fibrosar-
comas.
Kakinuma et al. (1995) also used thermosensitive lipo-
somes containing cis-diaminedichloroplatin (CDDP) to
6o deliver cytotoxic doses to brain tumors by dissolving the
liposomes with localized brain heating. The investigators
studied the anti-tumor effect on rat malignant glioma. Ten
days after tumor inoculation, the rats were assigned to one of
six treatment groups: control, free CDDP, hyperthermia, free
65 CDDP+hyperthermia, liposomes containing CDDP (CDDP-
liposomes), and CDDP-liposomes+hyperthermia. Lipo-
somes containing CDDP or free CDDP were injected via the
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3
tail vein. Brain tumor heating was administered by means of
a radiofrequency antenna designed for rat brain. The rats
treated with CDDP-liposome+hyperthermia had the longest
survival time and the tumor CDDP level of this group was the
highest when compared to the other groups. Histophathologi-
cal examination showed that tumor cells were necrotized but
surrounding normal brain tissue remained undamaged. The
greater anti-tumor effects suggested that the combination of
thermosensitive liposome and localized hyperthermia better
focused anti-tumor drugs to the tumor.
Thermosensitive liposomes designed for drug release by
hyperthermia have been tested at different local tissue tem-
peratures (Kakinuma et al., 1996). Four groups were studied:
the first received free Cisplatin (cis-diaminedichloroplatin,
CDDP); the second received free CDDP and above 41° C.
local brain heating for 30 minutes; the third group received
liposomes containing CDDP (CDDP-liposomes); and the
fourth group received CDDP-liposome and above 41° C.
local brain heating for 30 minutes. Brain CDDP levels were
significantly higher in group 4, while those in the other groups
were undetectable. The present inventors have also studied
the distribution of Evans blue dye (Eb) in the artificially
heated region of dogs' brain. One group received free Eb and
the other group received liposomes containing Eb (Eb-lipo-
some). While the extravasation of free Eb was localized in
regions heated to greater than 44° C., that of Eb-liposome was
extended up to the regions heated at 41 ° C. It appears that the
use of thermosensitive liposomes and hyperthermia not only
contributes to the brain tumor killing as direct thermal killing
does, but also helps to increase the concentration of chemo-
therapeutic drugs into the tumor invaded zones with mild
local hyperthermia of only 41' C.
A method of localizing a drug carrier that has been
described is the inclusion of magnetic particles in the carrier.
The encapsulation of oil-suspended magnetic particles into
microcapsules with hydrophilic, organic colloidal mem-
branes is described in U.S. Pat. No. 2,971,916. The magnetic
particles were used to direct the microcapsules to a magne-
tized location on a paper medium, where the capsules were
crushed to deliver an ink or stain to the paper.
Microspheres for intravascular administration comprising
magnetic particles in a biodegradable carrier are described in
U.S. Pat. Nos. 4,247,406 and 4,345,588. The microcapsules
described in these patents comprise magnetic particles
embedded in a polyamino acid matrix, such as albumin,
which also acts as a carrier for a therapeutic drug. The micro-
capsules are infused into an artery that feeds a particular
capillary bed and are then immobilized by the application of
a magnetic field across the capillary bed. The microcapsules
are held in the bed by the magnetic field until the polymer
matrix is dissolved by proteolytic enzymes, or they may be
drawn into the surrounding tissues by application of a stron-
ger field. As described in these patents, when these carriers
are drawn into tissue in order to directly deliver the drugs,
they become immobilized in the tissue where they remain
after the field is terminated.
Liposomes encapsulating magnetic particles are described
by Chang in U.S. Pat. No. 4,652,257. These liposomes are
also used to localize a chemotherapeutic drug in a capillary
bed by application of a magnetic field. After the liposomes are
immobilized at the target site, the magnetic particles are
vibrated by application of an oscillating magnetic field. The
particles are vibrated in order to destabilize, or to rupture the
lipid membrane, thus releasing the drug. The liposomes
described by Chang are small (on the order of 1-2 microme-
ters with ferromagnetic particles of about 100 to 1000 ang-
stroms), and are further limited in that only hydrophilic drugs
4
can be delivered from the liposomes. The small size of these
liposomes limits their utility because the size and shape is a
factor in the distribution and drug delivery of the liposomes in
the tissues. Additionally, in the liposomes described by
5 Chang, it is the mechanical force of the vibrating ferromag-
netic particles that destabilizes or ruptures the membrane,
rather than any local heating effect.
It is evident, therefore, that improvements are still needed
to address certain drawbacks of conventional liposome or
10 
microcapsule delivery systems. Delivery of a variety of active
drugs to a specific site in the body with a liposome formula-
tion still presents difficulties, for example. There is a need for
a system that would address certain disadvantages of ther-
15 mosensitive liposomes for drug delivery. These delivery sys-
tems are primarily useful for drugs that diffuse out of the
carrier across the outer phospholipid bi-layer membrane, orin
liposomes that are phagocytized by a particular cell type.
Thermosensitive liposomes may be melted by local hyper-
20 thermia, but unfortunately, methods for creating hyperther-
mia in local tissues are not precise and are largely dependent
on the local tissue composition. Heating may also be coun-
teracted by blood flow cooling. Thermosensitive liposomes
(or microcapsules) are limited to those having outer mem-
25 brans that can be melted at temperatures below those that
cause permanent damage to healthy tissues, usually a maxi-
mum of 41-44° C. In those methods in which heating or
mechanical forces are used to disrupt or melt the liposome
membrane, or even melt a hole in the membrane, the phos-
30 pholipid bilayer will rapidly extend to close off the hole and
thereby re-form the lipid bilayer. There is a need, therefore for
a method of controlled delivery of a drug at the tumor site
without depending on passive diffusion, local hyperthermia
of tissues, or temporary phase changes in the outer mem-
35 bran.
BRIEF SUMMARY OF THE INVENTION
The present invention addresses these and other drawbacks
40 in the prior art by providing compositions and methods com-
prising multi-layered liquid microcapsules that are composed
of a polymeric outer skin or membrane surrounding immis-
cible fluid compartments containing drugs in either solid,
crystalline or dissolved states. The microcapsules may also
45 contain metal particles such as ferromagnetic particles or
other magnetic particles that become heated by induction to a
controllable temperature when exposed to an external elec-
tromagnetic field or other forms of activating energy. The
microcapsules are designed so that the magnetic particles
50 may be heated to their characteristic Curie temperature(Curie
point) by exposure to an electromagnetic field, and will melt
holes in the outer skin of the microparticles, designed to have
a melting temperature that is less than the Curie temperature,
thus releasing the contents (drugs) without causing wide-
55 spread damage to the surrounding tissues. These magnetic
particles typically have a size range of 0.01 to 50 microns, and
preferably not more than Vio of the diameter of the microcap-
sule containing the magnetic particle.
The magnetic particles that are contained in the microcap-
60 sules have a specific absorption rate (SAR) when exposed to
an electromagnetic field, which is different from that of nor-
mal cells or tissues, and the particles may be designed to have
a characteristic maximum temperature (Curie point), at
which the magnetic material loses it thermal conductivity or
65 magnetic permeability and will not heat further upon contin-
ued exposure to the magnetic field. The microcapsules are
also designed so that the melting temperature of the outer
US 7,968,117 B1
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polymeric skin or membrane of the microcapsules is less than
the Curie point of the magnetic particles within that micro-
capsule.
The magnetic particles may be composed of a variety of
metals including ferromagnetic particles, such as Fe 3 O41 iron
carbonyls and combinations of various transition metal
oxides. The inventors have demonstrated the utility of
ceramic coated particles comprising oxides of iron, nickel
and zinc, such as particles comprising about 66 wt % Fe1031
about 9 wt % NiO, and about 25 wt % ZnO. Additional metals
that may be used in the particles described herein include, but
are not limited to cobalt, copper, gold, silver and combina-
tions thereof, including copper containing gold and silver
alloys. The magnetic material used in microcapsules as
described herein is also typically covered by a material such
as a ceramic that is compatible with the liquids within the
microcapsule and with the drug or active agent. Although the
particles described herein are coated with ceramics, other
coatings that are compatible with the liquid phases and drugs
or solvents to be used in the microcapsules. Ceramics were
chosen for the exemplary microcapsules described below
because of their low antigenicity, they are not chemically
reactive with the solvents or drugs used in the microcapsules,
and the protect the metal from oxidation. Alternate coatings
would include, but not be limited to methacrylates, alginates,
dextran, polyacrylates, polyvinyl pyrrolidone (if the ferrous
material is fully oxidized).
For use in clinical applications, the particles may have a
Curie temperature of from about 41'-44' or even up to as high
as about 80 to 95° C. Such high temperatures may be utilized
in the microcapsules because the small magnetic particles are
a point heat source rather than a tissue hyperthermia tech-
nique, which could never be used at such high temperatures
without causing extensive tissue damage. With the microcap-
sules of the present invention, it is contemplated by the inven-
tors that even a Curie point of 95° C. would cause collateral
damage in only a few neighboring cells. In the practice of the
invention, one may use an electromagnetic field with a fre-
quency of about 85-95, or even about 100 kHz, a strength of
about 1500-2000 Amps/m, although frequencies below about
500 KHz are also acceptable.
Certain compositions may also contain mixtures of micro-
capsules in which some capsules contain particles with dif-
ferent Curie temperatures than others, or microcapsules with
polymer membranes that have different melting temperatures
so that one can effect multiple releases of drug with a single
infusion. Of course, one may release different drugs at differ-
ent temperatures, or one may effect multiple releases of the
same drug. This allows a physician to release part of the drug
under control of an electromagnetic field, and then later
release more drug by using a different field power or time, or
to release different drugs separately, still from a single infu-
sion or injection. The invention, therefore, provides a flex-
ibility that is a distinct advantage over prior methods of con-
trolled delivery.
In a method of using the microcapsules, after the micro-
capsules reach a target site such as a tumor, either by direct
injection or infusion, the microcapsules are exposed to an
external electromagnetic field that is tuned to the maximum
SAR of the magnetic particles contained in the microcap-
sules. This method may include exposure of microcapsules
entrapped in tissues of a subject where the exposure is by
external administration of the electromagnetic field through
the subject's skin and outer tissues. This energy is absorbed
by the magnetic particles which are heated to their Curie
temperature without heating the surrounding tissue. The
heated magnetic particles melt a hole or perforation in the
6
outer skin of the microcapsules, thereby lysing the microcap-
sules and providing a conduit for rapid release of the drug by
bulk fluid flow out of the microcapsules and/or diffusion of
the drug out of the hole created in the membrane. The released
5 drug is then in contact with cells at the local site. It is under-
stood that, although the heating of the particles within the
microcapsules does not require heating of the local tissue, that
the compositions and methods described herein may be used
in conjunction with local hyperthermia therapies where
to desired. In certain embodiments, the microcapsules may be
exposed to an electromagnetic field of up to 500 KHz, and in
certain embodiments, around 100 KHz, or alternatively to
from about 6.78 to 27.12 MHz radiofrequency, from about
15 915 to about 2450 MHz microwave radiation, or to ultra-
sound.
In the practice of the invention, virtually any drug may be
encapsulated, including both hydrophilic and lipophilic
drugs. Certain embodiments include the encapsulation of an
20 anti-cancer drug, such as cis-platin, doxorubicin, daunorubi-
cin, paclitaxel, aziridinylbenzoquinone, muramyltripeptide,
5-fluoruracil, and other types of drugs that would include, but
not be limited to anesthetics, systemic antibiotics, antipara-
sitics, systemic quinolones, anti-infectives, anti -inflammato-
25 ries, aminoglyco sides, cephalosporins, penicillins, antidotes,
anti-cholinesterases, metal poisoning antidotes, antineoplas-
tics, cytotoxic agents, hormones, steroids, immunomodula-
tors, cytokines, interleukins, systemic antivirals, systemic
antifungals, biologicals, alpha-antitrypsin, bone metabolism
3o regulators, hypercalcemic agents, cardiovascular agents, beta
blockers, cerebral vasodilators, cerebral metabolic enhanc-
ers, cholinesterase inhibitors, colony stimulating factors,
granulocyte-colony stimulating factors, granulocyte mac-
rophage-colony stimulating factors, vasopressors, local dia-
35 betic agents, diagnostics such as CT scan enhancers and
angiocardiography agents, adenosine deaminase deficiency
agents, gonadotropin inhibitors, adrenal cortical steroid
inhibitors, gonadotropin releasing hormone stimulants, vaso-
pressins, urofollitropins, muscle relaxants such as neuromus-
40 cular blocking agents, prostaglandin analogs, prostaglandins,
prostaglandin inhibitors, respiratory therapy agents, anticho-
linergics, beta andrenergic stimulators, sympathomimetics,
and thrombolytics. In certain embodiments, the drugs may be
enzymes, or proenzymes that may be encapsulated and acti-
45 vated by mixing as described in a related application by the
same inventors, entitled "In Situ Activation of Microcap-
sules" incorporated herein by reference. In addition to the
methods of mixing immiscible layers described elsewhere, in
microcapsules containing magnetic particles, one can facili-
50 tate internal mixing by exposing the microcapsules to an
oscillating magnetic field.
As such, certain embodiments of the present invention may
be described as methods of treating a tumor in a subject
comprising: obtaining a pharmaceutical composition com-
55 prising a plurality of microcapsules in a pharmaceutically
acceptable solution, each microcapsule comprising two or
more immiscible liquid phases enclosed in a polymer shell
having a melting temperature, magnetic particles within the
microcapsules having a Curie temperature higher than the
60 melting temperature of the polymer shell, and contained in a
liquid phase in contact with the polymer shell, and an anti-
cancer drug contained in a liquid phase; administering the
pharmaceutical composition to the subject in a manner effec-
tive to place the microcapsules within or adjacent to the
65 tumor; and applying a magnetic field to the microcapsules
effective to heat the magnetic particles to their Curie tempera-
ture and melt at least a portion of the polymer shell.
US 7,968,117 B1
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In certain embodiments of the invention, the microcapsules	 temperature of the polymer shell and further wherein the
may also contain a radiocontrast media, or a medium that	 microcapsule is made by the method comprising: formulating
becomes radio-opaque through a change of oxidation state	 a first phase comprising a first solvent, a first polymer soluble
when exposed to energy. The radiocontrast media to be used
	
in the first phase and insoluble in a second phase, a co-solvent,
may include, but is not limited to a halogenated oil, such as for 5 oil, and water; formulating the second phase immiscible with
example, halogenated poppy seed oil, cotton seed oil, soy- 	 the first phase, the second phase comprising a second solvent,
bean oil, safflower oil, corn oil, olive oil, sunflower seed oil, 	 a second polymer soluble in the second phase and insoluble in
sesame seed oil, or canola oil. 	 the first phase, a surface active agent, and a salt; the surface
The microcapsules of the invention can be separated by 	 active agent having a hydrophilic/lipophilic balance value
filtration or other means known in the art to obtain a popula- io greater than that of the first polymer; the second polymer
tion of microcapsules of a particular size range that is pre-	 having a hydrophilic/lipophilic balance value lower than that
ferred for a particular use. Typically, microcapsules of 1-20 	 of the surface active agent; creating an interface between the
micron diameter are optimum for intravenous administration, 	 first and second phases in a manner that limits fluid shear to
whereas, 50-300 micron diameter microcapsules are used for 	 between about 1 to 100 dynes/cm2, if carried out under con-
intraarterial delivery and 300 micron or greater for intraperi- 15 ditions of greater than or about equal to 1 gravity, or between
toneal administration. In each size range, highly uniform	 about 2 to 30 dynes/cm2, if carried out under conditions of
microspheres are needed for maximum packing densities and
	
less than or about equal to 1x10-2 gravity, and maintains
maximum drug payload delivery to target organs or tumors. 	 adsorptive surface characteristics at the interface. It is under-
Therefore, one may obtain microcapsules of from about 1 to 	 stood that the magnetic particles are contained in the liquid
about 500 microns in diameter, or from about 300 to about 20 layer that lies next to the membrane, which may be an aque-
500 microns in diameter, or from about 30 to about 50 	 ous or hydrocarbon layer depending on the particular appli-
microns in diameter, or even from about 1 to about 20 microns 	 cation.
in diameter. As is known in the art of chemo-embolization, 	 Processes and compositions are provided by the present
particles of a certain size will form a part of an embolization 	 invention which overcome certain of the limitations of prior
in different areas such as the arterial, lung capillaries, venous, 25 methodology for forming microcapsules. In particular, meth-
or even peritoneal systems of a body. Microcapsules may be 	 ods and compositions are provided which form multilamellar
designed, then to be used in a chemo-embolization applica-	 microcapsules having alternating hydrophilic and hydropho-
tion, or they may be designed to pass freely through the	 bic liquid layers, surrounded by flexible, semi-permeable
capillaries or circulation of a subject in order to reach a target 	 hydrophobic, outer membranes which can be tailored specifi-
site. In the practice of the invention, one may choose micro- 30 cally to control the diffusion rate. In particular, the methods of
capsules of a particular size so that the microcapsules will 	 making microcapsules provided by the present invention do
occlude an arterial or venous vessel, for example at the site of 	 not rely on batch processes such as density-driven phase
a disease. Such a disease site may be a thrombosis, a wound, 	 separation and stratification into horizontal layers, mechani-
a site of infection, a lipid deposit or even the vasculature of a 	 cal mixing or solvent evaporation. Encapsulation of cytotoxic
tumor. Because the microcapsules contain magnetic particles, 35 or labile drugs in such microcapsules enables targeted deliv-
they may also be localized by application of an electromag- 	 ery and sustained release kinetics that are not currently avail-
netic field as is known in the art, except that care must be taken 	 able with intravenous injection.
not to heat the particles prematurely.	 The invention provides, in one aspect, methods of making
The drug precursors of the present invention are in certain	 a multi-layered microcapsule. The term microcapsule as used
cases a proenzyme or a zymogen. A proenzyme is an inactive 4o herein is a general term which can include any spherical
enzyme precursor that can be activated by cleavage of one or 	 microscopic vesicle including microspheres, micelles,
a few specific peptide bonds. In certain embodiments the 	 inverted micelles, bilayer vesicles and liposomes. The term
proenzyme may be a pro-thrombolytic enzyme, or a pro-	 microcapsule as used herein is also a more specific term
urokinase, or a pro-tissue plasminogen activator. 	 which refers to a microcapsule that comprises at least two
Certain embodiments of the invention will include the use 45 layers, one of which is innermost and is substantially com-
of fluorinated pyrimidine or purine analogs such as the pro- 	 pletely enclosed within the other. In a distinct break from
drug Floxuridine (Fluorodeoxyuridine) which is converted to 	 traditional methods for making microcapsules, the methods
the inhibitor 5'-monophosphate nucleotide (F-UMP) by thy-	 of the invention rely on low fluid shear, interfacial coacerva-
midine kinase. Other embodiments may utilize the oxidation, 	 tion and liquid-liquid diffusion process, particularly as devel-
reduction or hydrolysis of a prodrug that results in activation, 50 oped for forming microcapsules that may contain both aque-
change in activity or in conformation. Another example may	 ous and hydrocarbon soluble drugs.
be the use of the prodrug 6-mercaptopurine, which is acti- 	 The terms multi-layered and multi-lamellar are used inter-
vated to 6-mercaptopurine ribonucleotide, the oxidation of	 changeably throughout the specification and claims and both
trimethadone to the active agent, dimethadione, the oxidation	 refer to the fact that the microcapsules of the invention com-
of phenacetin to methemoglobin, or the reduction of chloral 55 prise at least two immiscible layers nested around one
hydrate to trichloroethanol. In addition, active agents may be 	 another. In some instances, the core layer will be hydrophobic
produced in microcapsules by contact with lipid soluble 	 in nature and will be completely surrounded by at least one
enzymes such as those isolated from the hepatic microsomes, 	 neighboring hydrophilic layer. In others, the core layer will be
or they may use doxorubicin derivatives activated by	 hydrophilic in nature and will be completely surrounded by at
lysozyme.	 60 least one neighboring hydrophobic layer.
As described herein certain inventions of the present dis-	 The basic method of the invention relies on liquid-liquid
closure may be compositions comprising a microcapsule 	 interactions. In the basic method, the first step entails formu-
comprising two or more immiscible liquid phases enclosed in	 lating a first phase or layer while the second step entails
a polymer shell, a drug precursor and possibly a drug activa-	 formulating a second phase or layer. The two phases or layers
tor, wherein the drug precursor and drug activator, when 65 are formulated to be immiscible with one another. For the
present, are contained in separate immiscible liquid phases, a 	 purposes of this invention, "immiscible" means that due to
magnetic particle with a Curie point higher than the melting 	 differences in density, viscosity or surface tension, the two
US 7,968,117 B1
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adjoining phases or layers form an interface resembling a
meniscus, and furthermore that the solubility of any compo-
nent in one phase is not more than 10 gm/100 ml in the
second, adjoining phase or layer.
Formulating the first phase or layer comprises combining a
first solvent, a first polymer soluble in the first phase, a co-
solvent, an oil, and water. The first solvent will typically
comprise about 75-90% by volume of the first phase. The first
polymer is selected to be one soluble in the first phase and
typically will comprise about 1-5% by volume of the first
phase. A small amount of a co-solvent is also added to the first
phase, which co-solvent may also function as a co-surfactant.
Oil comprising about I-10% by volume is also added to the
formulation. The first phase will also contain about 1-5%
water by volume.
The method next calls for formulating a second phase
immiscible with the first phase. The second phase comprises
a second solvent, a second polymer soluble in the second
phase, a surface active agent, and a salt. The relative, approxi-
mate volume percentages of these constituents is about
70-98% second solvent, 1-10% second polymer, 14% sur-
face active agent, and 0-3% salt.
In order to ensure that the liquid-liquid interactions neces-
sary to form the microcapsule will occur, certain of the con-
stituents of each phase are selected relative to one another.
Thus, the surface active agent in the second phase is selected
such that it will have a hydrophilic/lipophilic balance value
greater than that of the first polymer constituent of the first
phase. Generally, the most useful surface active agents have
been found to be those which are nonionic and which have a
hydrophilic/lipophilic balance value of 10.0 or greater. Next,
the second polymer constituent of the second phase is
selected to have a hydrophilic/lipophilic balance value lower
than that of the surface active agent constituent of the same
phase. While not an exhaustive list, certain hydrophilic/lipo-
philic balance values of materials which may be used in the
formulations of the invention are provided below.
Hydrophilic/Lipophilic Balance (HLB)
(McCutcheon 1979)
Compound HLB
Glycerol trioleate 0.8
Cholesterol 1.0
Triglyceride of coconut oil 1.4
Sorbitan trioleate 1.8
Sorbitan tristearate 2.1
Glycerol monooleate 2.7
Mono and di glycerides of fat burning fatty acids 2.8
Glycerol Monostearate (gms) 2.8-5.0
(3.8 preferred)
Propoxylated ethylene diamine plus ethylene oxide 3-28
Mono/diglyceride 3.2
Glycerol mono coconut 3.4
Mono/diglyceride 3.5
Propylene glycol mono fatty acid ester 3.5
Monoethoxyl lauryl ether 3.6
Stearyl lactyl acid 3.8
Hydrogenated cottonseed oil 3.8
Sodium lauryl sulfate 4.0
Mono and diglycerides with citric acid or 4.2-4.6
lactylic ester or fatty acid
Ethoxylated fatty amine (2 moles ETC) 4.5
Diethylene glycol monosteamte 4.7
Sorbitan monopalmitate 4.7
Diethylene glycol monosteamte and oleate 4.7
Ethoxylated (2) cetyl ether 5.3
10
-continued
Compound	 HLB
Glycerol Monoricinoleate 6.4
5	 Glycerol monolaurate 6.8
Triglycerol mono stearate 7.0
Polyethylene glycol (400 dioleate) 7.2
Lanolin sterol 8.0
Ethoxylated nonyl phenol (CO-420 & CO 850) 8.0-16.0
Polyethylene glycol (400) distearate 8.2
10	 Sorbitan monolaurate 8.6
Ethoxylated sorbitan fatty acid esters and 9.0
alkyl/aryl alcohol
Anhydrous lanolin 10.0
Polyethylene glycol monosteamte 11.0
Polyethylene glycol 400 11.2
15	 Ethoxylated (10) cetyl ether 12.9
Ethoxylated glycerol monostearate (gms) 13.1
Sorbitan monostearate 14.9
Sorbitan monooleate with 20 moles ethylene oxide 15.0
Ethoxylated (20) oleyl ether 15.3
Ethoxylated (20) stearyl cetyl ether 15.8
Ethoxylated castor oil 18.0
20	 Nonyl phenol polyethylene glycol ether 18.1
Polyethylene glycol 600 mono laurate 19.6
Sodium lauryl sulfate 40
Propylene glycol monosteamte 40
Hydroxylated lanolin sodium oleyl sulfate 42
Blends of GMS and sorbitan monooleate 52
25	 with 20 mols ethylene oxide
The basic method next involves creating an interface
between the first and second phases. The creation of the
30 interface is achieved in such a way that minimal shear and
mixing occurs between the phases. The two immiscible
phases are brought together in such a mechanical manner that
the fluid shear properties are controlled to low levels, typi-
cally below about 12 dynes/cm2, and such that the adsorptive
35 surface properties at the immiscible interfaces are not signifi-
cantly altered. Although the exact mechanisms are not fully
understood, the inventors believe that the maintenance of
certain surface properties, such as the surface tension, Helm-
holtz charge distribution (electrical double layer), and parti-
40 tioning of the surfactant molecules between the immiscible
phases must remain substantially intact so that lateral phase
separation can occur in a manner which allows simultaneous
formation of multiple liquid interfaces (oil/water or water/oil)
and which results in microcapsules having alternating spheri-
45 cal shells of hydrophilic and hydrophobic liquid layers. This
is believed to be the mechanism for the formation of multi-
lamellar vesicles which are formed in a single step. Although
this can best be demonstrated under microgravity conditions,
wherein buoyant convection is absent and diffusion-driven
50 convection and surface tension differences predominate, this
also can be accomplished in unit gravity conditions by bal-
ancing the density differences between the two liquid phases
or by any other mechanical means which prevents excess fluid
shear from significantly altering the normal adsorptive sur-
55 face properties which are determined by the chemical com-
position of the formulas and the interfacial phenomena
among the solvents, polymers and surfactants. In a preferred
embodiment, the creation of the interface will occur by slid-
ing individually separated compartments containing the two
60 phases into register with one another in a manner that sub-
stantially limits shear and provides gentle mixing.
In the final step of the basic method, conditions are estab-
lished in order to substantially limit all mixing between the
interfaced liquid phases. In the most preferred environment,
65 the two phases would be allowed to interact at their interface
without agitation, stirring, shearing or like force. It is pre-
ferred to also limit even those quiescent forces such a gravity-
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controlled sedimenting, phase separation into stratified lay-
ers, shifting, drift and the like. Thus, in certain preferred
embodiments, only chiefly diffusion-driven convection and
interfacial coacervation is used to spontaneously form micro-
capsules, as the chemical formulations of the different phases
assist in lowering the surface free energy across the interface.
It is also at this time that formation of the polymeric outer
coating is initiated.
In one embodiment, the two liquids thus formulated are
separated into distinct compartments or spaces which spaces
are each connected to a central diffusion chamber into which
each compartment can deliver its resident liquid loading. The
compartments are initially closed to access into the central
diffusion chamber so that the first and second liquids are kept
apart from one another and not allowed to interact. While it is
possible to use any number of devices to achieve this separa-
tion, a preferred device is a device like the Materials Disper-
sion Apparatus (MEPS) described in more detail elsewhere.
Preferred devices are also described in a related US Patent
Application by the same inventors and John M. Cassanto filed
concurrently with the present application and entitled,
"Microencapsulation and Electrostatic Processing Device."
The separation of the two liquids is maintained until both
liquids and the device containing them can be placed in an
environment in which convective mixing may be minimized,
such as in a microgravity environment.
The methods of the invention are slightly different depend-
ing upon whether the first solvent is selected to be organic or
aqueous. Where an organic solvent is used to formulate the
first phase, that organic solvent is selected from the group of
organic solvents consisting of ethyl alcohol, methyl alcohol
and isopropyl alcohol. Where an organic first solvent is used
to formulate the first phase, the first polymer is selected to be
one soluble in the organic solvent selected. Such a first poly-
mer may be selected from the group of polymers consisting of
glycerol monosterate, glycerol monooleate, glycerol mono-
laurate, glycerol dioleate, glycerol disterate, cholesterol, stig-
masterol, phytosterol, campesterol, and lecithins such as
phosphatidyl cholines (e.g., Centrolex-F®).
Where the first solvent is aqueous, a slightly different
approach is taken. In those instances, the first polymer is
again requisitely soluble in the first aqueous phase and may be
selected from the group of polymers consisting of polyvinyl
pyrrolidone, polyvinyl alcohols, gelatin, gum tragacanth, car-
rageenan, Karaya gum, Guar gum, gum arabic, alginates,
carboxymethyl cellulose, hydroxypropyl cellulose, carbox-
ypropyl cellulose, and lecithins.
Regardless of the formulation with an aqueous or organic
first solvent and polymer, the methods of the invention both
use a co-solvent which may be selected from the group of
co-solvents consisting of C 3 -C$ alcohols, tetrahydrofuran,
dioxane, acetonitrile, dimethylformamide, dimethylaceta-
mide, and dimethyl sulfoxide. Similarly regardless of the
organic/aqueous nature of the first solvent and polymer used,
the methods of the invention add to the formulation of the first
phase an oil. These oils may be selected from the group of oils
consisting of unsaturated oils such as poppy seed oil, olive oil,
peanut oil, sesame oil, cotton seed oil, soybean oil, safflower
oil, corn oil, sunflower seed oil and canola oil or saturated oils
such as mineral oil, long chain paraffinic oil, and liquid pet-
rolatum. In a preferred embodiment, poppy seed oil will be
halogenated, or in certain embodiments, iodinated to form
iodinated poppy seed oil (IPO) and incorporated into a micro-
capsule as a marker or tracer for tracking the presence of the
microcapsule once injected via radiocontrast detection meth-
ods known well to those of skill in the art of radiography.
Whether the method involves an organic or an aqueous first
solvent, the second polymer, the surface active agent and the
salt may each be selected from a particular group of such
compounds. The second polymer may be selected from the
5 group of polymers consisting of polyethyleneglycol
400-20000 daltons, dextran 1000-100,000 daltons, polyvi-
nylpyrrolidone, polyvinyl alcohols, gelatin, gum tragacanth,
carrageenan, Karaya gum, Guar gum, gum arabic, alginates,
carboxymethyl cellulose, hydroxypropyl cellulose, carbox-
io ypropyl cellulose, and lecithins. The surface active agent is
selected from the group of surface active agents consisting of
sorbitan monooleate treated with ethylene oxide, dextran,
polyethylene glycol, C12-C20 fatty acids, 2-amino-2-methyl-
1-propyl aminomethyl propanol amphoteric salts and quater-
15 nary ammonium salts. The salt is selected from the group of
salts consisting of NaCl, KCl, CaC121 MgCl2, quaternary
ammonium salts such as cetyl trimethylammonium bromide
and 4-methoxy-4(3-phosphatidyl choline)spiro(1,2-dioxet-
ane-3-g,l-adamantane) disodium salt.
20 Multi-layered microcapsules, with both hydrophobic and
hydrophilic drug compartments, as produced by the methods
of the invention enable diffusion of complimentary drugs
from the same microcapsule, e.g. antibiotics and immuno-
stimulants to treat resistant infections or multiple fibrinolytic
25 drugs to dissolve emboli. Co-encapsulation of radio-contrast
medium as provided herein enables oncologists to monitor
the delivery of anti-tumor microcapsules to target tumors
using computerized tomography and radiography that track
the distribution of microcapsules after release from the intra-
3o arterial catheter. Such microcapsules will have important
applications in chemotherapy of certain liver, kidney, brain
and other tumors.
The diameters of microcapsules possible to attain using the
methods of the invention are also of particular usefulness in
35 medical applications. Thus, whereas prior art methods have
been able to routinely produce microcapsules over 1-10
micron average sizes, the present invention's methods pro-
vide similarly-sized microcapsules of 1-20 micron diameters
for intravenous administration. Also provided are 25-300
40 micron sized microcapsules particularly useful in interarterial
chemoembolization of tumors, and microcapsules in the
range of 300 micron and greater diameters useful in interperi-
toneal or intramuscular administered drugs.
The pharmaceutical composition encapsulated in the
45 microcapsule may be one soluble in aqueous solutions or may
be one soluble in organic solutions. This, of course, governs
the selection of the phase or layer in which the pharmaceutical
composition is formulated. The microcapsules of the inven-
tion and methods for producing them are of particular utility
50 when formulating organic-soluble drugs as these types of
drugs are otherwise very difficult to administer. The pharma-
ceuticals may be those selected from the group of suchwidely
diversified pharmaceutical compositions as that consisting of
cytotoxins, proteases, cytokines, anti-nauseants, steroids,
55 anti-fungal agents, fibrinolytic enzymes, and antibiotics. The
inventors have successfully encapsulated representatives of
these classes of pharmaceuticals using the methods of the
invention. It is also possible to incorporate a pharmaceutical
composition which is not initially dissolved in one or another
60 of the phases or layers, but rather which drug is in suspension.
As noted above, depending upon its solubility and upon
where the pharmaceutical chemist wishes to locate the drug,
it is possible to formulate a drug in any of the phases or layers,
by dissolving or suspending the drug as needed. Upon melt-
65 ing of the polymer shell by heating the magnetic particles, any
of such layers and their contents will leak out of the micro-
capsule.
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The methods of the invention surprisingly demonstrated
the ability to package very high concentrations of drugs in the
layers formed. It is possible, using the methods of the inven-
tion, to formulate a pharmaceutical at a concentration suffi-
cient to allow nascent crystal formation within the microcap-
sule once it is formed. These microcapsules, due in one regard
to their being constructed with outer polymeric coatings, are
also particularly flexible yet rugged (able to withstand shear
forces greater than 10 dynes/cm'). As will be related specifi-
cally below, microgravity experiments, on sounding rockets
(1989-92) and Shuttle missions STS-52 (1992) and STS-56
(1993) using an automated Materials Dispersion Apparatus,
produced multi-lamellar microcapsules containing both Cis-
platinum (anti-tumor drug) and iodinated poppy seed oil (a
non-radioactive, radiocontrast medium), surrounded by a
polymeric skin. Microcapsules formed with amoxicillin (an-
tibiotic) or urokinase (a clot dissolving enzyme), co-encap-
sulated with IPO, were still intact after two years after return
to 1 xg environments. In many instances, microcapsules were
formed with the Cis-Platinum or amoxicillin so concentrated
that crystals of the drugs formed inside.
In certain embodiments of the methods of the invention,
pharmaceutical compositions will be incorporated into the
microcapsule. Where such pharmaceuticals are thusly incor-
porated, they may be introduced initially as a solute or as
particulates suspended in one or the other of the liquids used
to formulate the layers of the microcapsules. In certain
embodiments, the pharmaceutical is introduced in one of the
phases or layers used to produce the microcapsule at a con-
centration sufficient to allow nascent crystal formation within
said microcapsule. Crystal formation may occur at or near the
time of formation of the microcapsule containing the dis-
solved pharmaceutical material. The aqueous solvent system
used to dissolve an aqueous-soluble pharmaceutical is
selected to permit water molecules to migrate away from the
drug-containing layer into the alcoholic mixture. The process
of crystal formation is likely to be promoted in this manner
after formation of the microcapsule. In fact, it is possible to
enhance the crystallization process after the microcapsule is
formed by controlled transport of the solvent phase or layer in
which the pharmaceutical to be crystallized is a solute. In
certain embodiments, the crystal thus formed may take up
most of the internal capacity of the microcapsule.
Surprisingly, the methods of the invention have demon-
strated a unique ability to encapsulate such saturated drug
solutions, and since the overall partitioning characteristics
between immiscible layers facilitates solvent transport out of
the aqueous layer, it is possible to concentrate the drug to the
point that formation of drug crystals occurs within the micro-
capsules. This ability of the microcapsules and methods of the
invention provides the maximum drug payload per microcap-
sule and the best drug release kinetics forprolonged treatment
at maximum drug diffusion rates.
Microcapsules containing a large volume component of
crystalline drug provide the most concentrated drug possible
when it is released at the target site. Until the crystals are
completely dissolved, the drug release rate is independent of
time (zero order release kinetics). When the crystals have
dissolved, the drug release rates revert to first order kinetics
(exponential with time). The encapsulated crystals of the
invention are in the range of 1-100 microns along one face.
Since these crystals are precipitated in situ, they are quite
different from the other commercially-available crystalline
drug delivery systems (e.g., Microcrystal(k) which use phos-
pholipids to encapsulate tiny particles or crystals of drugs
with an average diameter of only 0.3-1.0 micron [Parik] and
Stern 1994].
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It is also possible to additionally treat the microcapsules
thus formed with additional steps. In some instances, the
methods of the invention, regardless of whether they initially
use an organic or an aqueous first solvent, formulate a third
5 phase comprising an oil or C21-C38 paraffin and, contact the
formed microcapsule with the third phase. In other instances,
the methods of the invention form a two-layered microcap-
sule, then formulate a third phase comprising an aqueous
solution and, contact the formed microcapsule with the third
10 phase. The basic method and alternatives are summarized
below.
15 Group 1 Group 2
Solution 1 Solvent 1 is a hydrocarbon Solvent 1 is aqueous
Polymers are hydrocarbon Polymers (skin) are water
soluble, selected to form the soluble, but can be extended
outer coating (typically of into organic phase (includes
20 lower HLB values) phospholipids) Ex.
Centrolex F
Co-solvents alcohols, Co-solvents same, but often
hydrocarbons (act as co- less
surfactants)
Oils saturated or unsaturated Oils same
25 oils Prodrug or activator Prodrug or activatordissolved (or suspended dissolved (or particulate)
particulate)
Solution 2 Solvent 2 aqueous Solvent 2 same
Polymers water soluble (PEG, Polymers same
Dextran)
Surfactants (typically higher Surfactants same but often
30 HLB value) less
Salts ionic, quaternary Salts same, but often
ammonium salts different
Prodrug or activator aqueous Prodrug or activator aqueous
soluble soluble
Solution 3 Oils hydrocarbons Oils same
35 Polymers hydrocarbon-soluble Polymers same
Drugs can be included Drugs can be included
--OR-- --OR--
Alternative aqueous solution Alternative aqueous solution
coatingadjuvants coating same
immunoglobulins polymer same
40 polymers—aqueous soluble surfactants same
surfactants
Traditional emulsion methods form a O/W/O (oil/water/
oil) or W/O/W (water/oil/water) liquid system which is
45 designed to retain the internal phase(s) within the external
solvent unless the emulsion is broken, whereupon the liquid
phases separate. In the methods of the invention, the use of
surfactants and co-surfactants permits formation of an emul-
sion of large spheroids (not small microspheroids) of one
50 phase dispersed in the otherphase configured in a sphere. The
sphere is also surrounded by another immiscible liquid layer
(opposite phase to that of the innermost liquid sphere) and
then (often) this multi-layered sphere is contained in another
opposite-phase liquid layer and finally the entire multi-lay-
55 ered sphere is contained in an outer skin. The results of the
process of the invention are not to forma traditional O/W/O or
W/O/W emulsion (which is a fine dispersion of one phase in
another), but rather to form multi-lamellar, alternating immis-
cible-layer microcapsules contained within a thin, semi-per-
60 meable outer skin. In the microcapsules of the invention, the
immiscible phases are distinct and separated according to the
surface tension characteristics of the liquids at each interface,
hence there is no true emulsion maintained by the surfactant
which could be broken.
65 Thus, in certain embodiments of the methods and compo-
sitions of the invention, the multi-layered microcapsule will
be produced which comprises at least three alternating layers
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or phases. Thus, if the first layer is an aqueous layer or core, 	 ment can be used to deliver very labile drugs which have very
the next layer may be an organic layer. This organic layer may	 limited shelf-lives or short biological half-lives whereupon
then be covered over by a second aqueous layer which forms 	 the activator (third phase) can be added just prior to intravas-
on its outer surface a polymeric skin. Conversely, the liquid at 	 cular administration such that the inactive drug becomes acti-
the core of the microcapsule may be an organic liquid layered 5 vated after the microcapsules have reached the target site.
over by an aqueous layer followed by another organic layer	 Upon activation, the microcapsules are exposed to an elec-
which forms a polymeric skin over the surface of the micro- 	 tromagnetic field effective to heat the magnetic particles, thus
capsule. Certainly, extension of these basic formulations may 	 melting the polymer shell and releasing the activated drug.
be envisioned where four or more layers are possible or where 	 This can maximize the therapeutic effectiveness of the short-
multiple skins or coatings are utilized. 	 io lived drug at the target site of action.
Whether used in conjunction with a two-layer microcap- 	 One or more of the phases of the microcapsule of the
sule or with microcapsules with more than two layers, the	 invention may further comprise fluorescent molecules
coatings of the present invention are of substantial utility,	 selected from the group of fluorescent molecules consisting
particularly when the methods are carried out at Earth-normal 	 of fluoresceins, cyanins, naturally fluorescent molecules, and
gravity. The coatings can be either substantially of a hydro-  15 rhodamines, and others excited between 260 and 700 nanom-
phobic nature or of a hydrophilic nature as described below	 eters. This is particularly useful where radiocontrast media
and are derived from addition of certain polymers in the initial	 are not desirable or where an additional tracking method is
formulations of the liquids used to make the microcapsules. 	 useful or where it is of value to monitor the presence or
Where hydrophobic coatings are used in conjunction with	 absence of a layer in the microcapsule, fluorescent molecules
drug-delivery systems, the coatings are selected for their 20 may be incorporated into the microcapsule of the invention.
complementary permeability to the drug to be delivered. The 	 Thus, for instance, as described more fully below, it may be
polymers are also selected for their flexible characteristics	 useful to incorporate a hydrophilic fluorescent molecule in
after formation and curing which is of particular utility during 	 the aqueous liquid in order to determine the relative location
intravascular transport and allows higher packing densities	 and number of aqueous liquid layers in a certain production
for forming emboli such as in chemoembolization therapy. 25 batch of microcapsules produced by the methods of the inven-
Thus, for example where a water-soluble drug is to be deliv- 	 tion.
ered, the drug is contained in an inner aqueous layer over	 Critical to the success of the methods of the invention is the
which is placed a coating permeable to the dissolved drug. In 	 substantial limitation of mixing between said phases to dif-
alternate embodiments, the drug may be more hydrophobic 	 fusion-driven convection and low fluid shear (preferably less
and will be contained in a hydrocarbon layer within the 30 than 50 dynes/cm2). One manner in which to so limit other
microcapsule. In either embodiment the drug may actually be	 types of mixing is to carry out the methods under micrograv-
a prodrug, and an activator may be contained in a layer immis- 	 ity. Microgravity is defined as a gravity force of less than
cible with the layer containing the prodrug. Preferably, the 	 1 x10-3 xg. Such gravitational environments may be achieved
coating material should be impermeable to solvents or oils. 	 in a variety of ways, at least some of which are detailed herein.
The coatings which have been observed to be deposited on the 35 For instance, microgravity may be achieved in certain trajec-
surfaces of the microcapsules of the invention are about 0.01-	 tories of sounding rockets. Even longer periods of micrograv-
2.0 microns thick where the coating is a hydrophobic coating, 	 ity may be obtained with temporary orbiters such as the space
and about 0.1-5.0 microns thick where hydrophilic coatings 	 shuttle. Relatively indefinite periods of microgravity may be
are deposited.	 obtained in permanent or semipermanent orbital space craft
The additional steps and third formulated phases may also 40 such as the orbital space station and other geosynchronous
be used advantageously to provide the microcapsule with 	 orbital satellites. The exposure of the first and second liquids
specific characteristics. Thus, the third phase may further 	 to microgravity has been found to be effective in forming the
comprise a pharmaceutical composition which is added to the 	 microcapsules of the invention where the exposure is at least
formed surface of the microcapsule. The third phase may also 	 6.5 minutes in duration, and later studies have shown that a
be used to add a pharmaceutical composition such as an 45 few seconds is sufficient. Certainly, as described more fully
adjuvant. The adjuvant may further comprise an immunoglo- 	 below, greater exposure periods have also been proven suc-
bulin, other protein, hydrocolloid or polysaccharide. This is	 cessful. The inventors have shown that periods of exposure as
of particular utility in designing microcapsules with unique 	 short as a few seconds will also produce adequate numbers of
immunologic, proteinaceous, surface charged, or other sur- 	 microcapsules.
face characteristics which makes them selectively adhere to 50	 In formation of microcapsules, however, the methods of
certain target tissues (cells) or renders the microcapsules 	 the invention will not necessarily use microgravity in order to
attractive to certain phagocytic cells (when the cells are the 	 limit mixing between the phases. Of course, such limitations
actual target for the therapeutic drug). Where the adjuvant is	 of mixing canbepromotedby carrying out the methods below
a hydrocolloid, it may be selected from the group of such	 ambient temperature. Limitation of interactions between the
hydrocolloids consisting of collagen, isoelectric gelatin, agar, 55 phases is best promoted by substantially balancing the spe-
gum arabic, gum tragacanth, alginates, cellulose derivatives, 	 cific gravity between said phases as is described below. The
guar gum, cyclodextrins, and carrageenans. The third phase	 formulations and methods necessary to achieve Earth-normal
may also further comprise a surface active agent. 	 microcapsule formation are described in greater detail herein.
The third aqueous phase can also contain a chemical acti- 	 In either case, or in combinations of these techniques, mixing
vator which acts upon the inactive form of the pharmaceutical 6o between the two phases may be chiefly the result of diffusion-
agent (drug) as it diffuses out of the inner layers of the micro-	 driven convection.
capsule. The function of the activator is to chemically convert	 The inventors have found that there is a greater size distri-
the inactive drug to its active form just before it is released	 bution which results from microencapsulation at Earth-nor-
from the microcapsule. This is illustrated when the pharma- 	 mal gravity. At least a partial reason for this wider size dis-
ceutical is a pro-enzyme and where the activator is another 65 tribution is apparently the inability under Earth-normal
proteolytic enzyme which cleaves the pro-enzyme at active 	 gravity to avoid certain sedimentation phenomena alone and
site to render the molecule biologically active. This embodi- 	 sedimentation effects combined with weight-related contact
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of sedimented microcapsules. These facts require some addi- 	 tion will not reform an intact membrane, and is designed to
tional manipulation under Earth-normal environments not	 avoid recognition and phagocytosis by immune cells, thereby
required in the 0-g environments namely, sieving of the 	 increasing the amount of drug delivered to the tissues. The
resulting microcapsules in order to generate more uniform	 multi-layered microcapsules of the invention can entrap mul-
fractions. Therefore, at Earth-normal gravity, the utility of the 5 tiple drugs in different solvent compartments and saturated
outer coating of the microcapsules of the present invention 	 solutions of drugs which may then form crystals inside the
become even more important. Enhancing the ruggedness of 	 microcapsule. Radiocontrast medium can be co-encapsulated
the Earth-normal microcapsules by curing and other steps as 	 with drugs in the same microcapsule. A magnetic resonance
related herein may also be used.	 contrast agent can also be encapsulated such as various met-
A preferred method of making a multi-layered microcap-  io allo-organic compounds including aqueous soluble ferrous
sule comprises: formulating a first phase comprising an	 gluconate, Gadolinium diethylene triamine pentaacetic acid
organic solvent selected from the group of organic solvents	 and hydrocarbon-soluble, iron pentacarbonyl.
consisting of ethyl alcohol, methyl alcohol and isopropyl 	 The microcapsules of the invention have been found to
alcohol, a first polymer soluble in the first phase selected from	 provide a surprisingly uniform distribution of diameters. This
the group of polymers consisting of glycerol monosterate, 15 uniformity is particularly important in its medical applica-
glycerol monooleate, glycerol monolaurate, glycerol 	 tions. The microcapsules thus produced can be used to deliver
dioleate, glycerol disterate, cholesterol, stigmasterol, phy- 	 several drugs which can be released sequentially to the target
tosterol, campesterol, lecithins such as phosphatidyl cholines 	 tissues through choosing magnetic particles with various
(e.g., Centrolex-F(k), a co-solvent selected from the group of 	 Curie points, for example. The deformable, liquid-filled
co-solvents consisting of C 3 -C$ alcohols, tetrahydrofuran, 20 microcapsules also have advantages over solid matrix micro-
dioxane, acetonitrile, dimethylformamide, dimethylaceta-	 capsules in achieving maximum packing density in blood
mide, and dimethyl sulfoxide, an oil selected from the group 	 vessels, thereby decreasing blood flow to target tissues. This
of oils consisting of poppy seed oil, olive oil, peanut oil, 	 enhances the therapeutic effect of combined drug delivery
sesame oil, cotton seed oil, soybean oil, safflower oil, corn oil, 	 and reducing the blood supply to vascular tumors (chemoem-
sunflower seed oil, canola oil (unsaturated oils), or mineral 25 bolization).
oil, long chain paraffinic oil, and liquid petrolatum (saturated 	 The methods of the invention result in more spherical,
oils), and water; formulating a second phase immiscible with 	 uniform size distributions of microcapsules. When compar-
the first phase, the second phase comprising water, a second
	
ing certain prior art equipment and methods for forming
polymer soluble in the second phase selected from the group 	 microcapsules (Microfluidics, Inc.), the inventors found that
of polymers consisting of polyethyleneglycol 1000-8000 dal- 30 even the preferred formulations disclosed herein were inca-
tons, dextran 1000-10000 daltons, polyvinylpyrrolidone, 	 pable of providing such uniformity with the prior art equip-
polyvinyl alcohols, gelatin, gum tragacanth, carrageenan, 	 ment. In certain instances, hardly any microcapsules formed
Karaya gum, Guar gum, gum arabic, alginates, carboxym-	 at all where mixing and vortexing were used to distribute one
ethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cel- 	 phase into the next. In others, poorly formed and non-spheri-
lulose, carboxypropyl cellulose, lecithins, a surface active 35 cal microcapsules resulted. In contrast to the failures of the
agent selected from the group consisting of sorbitan 	 prior art methods, the methods of the invention were success-
monooleate treated with ethylene oxide, dextran, polyethyl- 	 fully used to generate uniform, spherical microcapsules both
ene glycol, C 12 -C20 fatty acids, cyclodextrins, PEG dextran	 under unit gravity and under microgravity conditions. Such
copolymer, PEG acrylates, lactides, galactides, chitosan,	 uniformity enables superior drug delivery. Enhanced unifor-
Zein®, carbapol, polyoxamers, quaternary ammonium salts, 40 miry also enables better dose distribution calculations for
and a salt selected from the group of salts consisting of NaCl, 	 establishing the therapeutic dose in the treatment of specific
KCl, CaC121 MgCl2, quaternary ammonium salts, such as
	 diseases, especially treatment of certain types of tumors.
cetyl trimethylammonium bromide, 2-amino-2-methyl-l- 	 Importantly, the methods of the invention allow the formation
propyl aminomethyl propanol, and 4-methoxy-4(3-phos-	 of larger-sized, multi-lamellar microcapsules (1-350 micron)
phatidyl	 choline)spiro(1,2-dioxetane-3-g,l-adamantane) 45 than heretofore possible. Such a capability allows multila-
disodium salt; the surface active agent having a hydrophilic/ 	 mellar microcapsules to be made specifically for inhalation
lipophilic balance value greater than that of the first polymer; 	 and deposition in the lungs. This uniformity allows facile
the second polymer having a hydrophilic/lipophilic balance 	 sieving or filtering of the microcapsule products in order to
value lower than that of the surface active agent; creating an 	 obtain highly uniform diameter fractions.
interface between the first and second phases in a manner that 50	 Most liposomes have a very small hydrophobic compart-
substantially limits fluid shear; and, substantially maintaining 	 ment and therefore can only carry small amounts of hydro-
adsorptive surface characteristics of said interface.	 phobic drugs. Contrastingly, the microcapsules of the inven-
Microcapsule products produced by any of the methods of	 tion have a relatively large hydrophobic liquid compartment
the invention are also claimed. The methods of the invention 	 which enables delivery of more hydrophobic drug per micro-
are used to form unique multi-lamellar, microcapsules, hav- 55 capsule. Moreover, the microcapsules of the invention have
ing alternating hydrophilic and hydrophobic liquid layers	 relatively large hydrophilic and hydrophobic compartments
surrounded by a flexible, semi-permeable, polymeric outer 	 which permits tandem delivery of both water soluble and
"skin". The outer skin which can be either hydrophilic or 	 non-water soluble drugs in the same microcapsule.
hydrophobic, is designed to allow controlled drug diffusion 	 As previously noted, the microcapsules of the invention
out of the microcapsule. The outer skin is also designed to 60 may contain polysaccharides. Inclusion of such polysaccha-
have a melting temperature below the Curie point of the 	 rides is one of several aspects of the methods of the invention
encapsulated magnetic particles, so that exposure to an elec- 	 that enhance the formation of the microcapsules. The inclu-
tromagnetic field will cause the melting of a hole or pore in 	 sion of injectable polysaccharides in the formulations of the
the skin, thus aiding in release or diffusion of dissolved
	
invention contributes to the driving forces that control phase
chemicals out of the microcapsule. 	 65 separation and phase partitioning of the entrapped drugs. The
Unlike any natural phospholipid or other component of cell	 polysaccharides also provide increased shelf-life and stability
membranes, the outer skin of the microcapsules of the inven- 	 of the parenteral suspensions. Use of the neutral salt solutions
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in the aqueous phase enhances micelle formation, lateral invention around the outer surface of the microcapsule avoids
phase separation, and increases the dispersion of microcap- being readily detected and largely eliminated by the reticu-
sules and their stability as they are formed. In certain embodi- loendothelial system (RES). The outer skin protects the
ments, phosphate buffered saline containing dextran may be microcapsules against shear forces encountered during
used.	 5 manufacturing processes and during transport within the vas-
The methods of the invention, in certain embodiments, cular system en route to the target tissues. The hydrophobic
utilize a non-phospholipid outer coating. The microcapsules outer membrane also can be designed to retard oxygen trans-
formed by this method are contained in a thin, semi-perme- port, thereby reducing oxidative degradation of the entrapped
able, outer membrane comprised of hydrophobic (e.g. mono- drug and improving the shelf-life of the parenteral suspen-
or polyglycerides or waxy-polymers) or hydrophilic poly- 10 sions. The flexible/deformable outer skin on the microcap-
mers (e.g., PVA or PVP), depending on the desired diffusion sules of the invention results in increased packing densities
release rate of the encapsulated drug. Thus, the coating has within vascular beds. This results in microcapsules superior
the advantage of allowing design of the appropriate drug to solid microspheres (e.g. gelatin, albumin or starch) com-
diffusion and release characteristics while avoiding certain of monly used for chemoembolization therapy against tumors.
the disadvantages of conventional liposomes (and lipid bilay- 15 The formulations used to produce the microcapsules of the
ers). In particular, the coating produced by the methods of the invention are summarized below.
TABLE 1
Formulas for Primary, Secondary and Tertiary Solutions
for Microencapsulation
Tertiary
Solution
Primary Solution Secondary	 (also can contain dissolved
(also can contain drug) Solution	 drug)
Group 1	 First Solvent (75-90%) Second Solvent water	 Oils (up to 100%)
ethyl alcohol (70-98%)	 IPO
methyl alcohol Polymers	 heavy mineral oil
isopropyl alcohol (1-10%)	 olive oil
Organic Co-solvent 0-20% polyethylene glycol 	 same as in
Cq Cs alcohols PEG - 400-20000	 primary soln.
tetrahydrofuran (THE) (polysaccharides)	 Paraffins
dioxane Dextran 4000-20000	 (C20 Cis)
acetonitrile (range 1000-100,000))	 Alternative
dimethylformamide (DMF)	 others	 Aqueous solutions containing-
dimethyl sulfoxide (DMSO)	 polyvinyl-	 Immunoglobulins
Polymers pyrrolidone	 Albumin
(1-5%) (monoglycerated) polyvinyl alcohols 	 Gelatin
glycerol monostearate	 Surfactants	 Hydrocolloids
glycerol monooleate 	 (ionic and non-ionic) 	 plant sterols
glycerol monolaurate (1-4%)	 phospholipids
(polyglycerides) sorbitan	 polysaccharides
glycerol dioleate monooleate plus	 starches
glycerol disteamte ethylene oxides	 cyclodextrins
(sterols) Dextran	 Polymers
cholesterol PEG	 Surfactants (1-4%)
plant sterols— C12 C20 fatty acid	 (ionic and non-ionic)
stigmasterol quaternary NH4	long chain
phytosterol salt	 celluloses
campesterol Additional Polymers	 Additional Polymers
(phospholipids) (1-10%)	 Same as secondary solution
lecithins (hydrocolloids)	 Dissolved Drugs
e.g., phosphatydl choline	 gelatin	 (1% to saturation)
(Centrolex-F°) gum tragacanth	 soluble therapeutic
Water (1-5%) water carrageenans
Oils karaya gum
(unsaturated or saturated) guar
(1-10%) gum
iodinated poppy seed oil 	 alginates
(IPO) (celluloses)
mineral oil celluloses
cotton seed oil (CMC, WEC,
olive oil HPC)
safflower oil Salts
canola oil (0.01-3%)
peanut oil NaCl KCI,
sesame oil CaCl2, quaternary NH4
corn oil salts,
Dissolved Drugs cetyl
(1% to saturation) PPD
Dissolved Drugs
(1% to saturation)
therapeutic of choice
Group 2 Aqueous First Solvent water	 Same as	 Oils (up to 100%)
(70-90%) Group 1	 Same as Group 1
Co-solvents (0-20%) Co-Solvents	 Alternatives
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TABLE 1-continued
Formulas for Primary, Secondary and Tertiary Solutions
for Microencapsulation
Tertiary
Solution
Primary Solution Secondary (also can contain dissolved
(also can contain drug) Solution drug)
C3 -Cs alcohols Same as primary solution Aqueous solutions
tetrahydrofuran (THF) Polymers (1-10%) Same as Group 1
dioxane Same as Group 1 Polymers
acetonitrile Surfactants (1-20%) Same as Secondary Solution
dimethylformamide (DMF) (ionic and non-ionic) Surfactants
dimethyl sulfoxide (DMSO) Same as Group 1 Same as Secondary Solution
Polymers hydrophilic Additional Polymers 1-10%	 Dissolved Drugs
(water soluble) Salts (0-3%) 1% to saturation
polyvinylpyrrolidone (PVP) Same as Group 1
polyvinyl alcohols (PVA) Dissolved Drugs
hydrocolloids 1% to saturation
gelatin
gum tragacanth
carrageenans
karaya gum
guar gum
alginates
celluloses CMC, CPC
phospholipids
lecithins
phosphatydl choline
Centrolex F
polysaccharides
corn starch
cyclodextrins
Oils (unsaturated or saturated)
1-10%
iodinated poppy seed oil
(IPO)
mineral oil
cotton seed oil
olive oil
safflower oil
canola oil
peanut oil
sesame oil
corn oil
Dissolved Drugs
1% to saturation
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	Where the microcapsules of the invention comprise a phar-	 pentaacetic acid (Gd-DTPA) used for nuclear magnetic reso-
	
maceutical composition, certain medically related advan- 	 nance imaging and hydrocarbon soluble agents such as iron
tages may be obtained. Thus, due to the uniformity and ease 45 pentacarbonyl which also may be used for NMR imaging.
	
with which the methods of the invention allow formation of	 Production of multi-layered microcapsules via the meth-
	
multilamellar microcapsules, co-encapsulation of multiple 	 ods of the invention which possess alternating hydrophobic
	
drugs is made possible. Thus, for instance, as will be	 and hydrophilic drug compartments allows for design ofmul-
	
described more fully below, co-encapsulation of drugs and 	 tiple-therapy microcapsules. Spontaneous formation of
radiocontrast medium in the same microcapsules is made 50 microcapsules with one or more large hydrophobic solvent
	
possible by the methods of the invention. Such co-encapsu-	 compartments increases the potential application for delivery
	
lation allows radiological monitoring of the tissue distribu-	 of more aqueous-insoluble drug at target sites with adequate
	
tion during intravascular delivery. Additionally, incorpora-	 vascular networks. By using the microcapsules made possible
	
tion of fluorescent-labels for entrapped drugs enables 	 by the methods of the invention, sequential diffusion of two or
accurate measure of the drug compartment volumes (using 55 more drugs out of the same microcapsule may be achieved at
	
fluorescent imaging techniques) and convenient determina-	 the target tissues. The incorporation of aqueous-soluble
	
tions of the drug loading efficiencies, particle size distribu- 	 cyclodextrin which can act as an internal hydrophobic drug
	
tions and measurement of shelf-life stability of the final 	 carrier is also made practical using the single step methods
	
parenteral suspensions. In some applications made possible 	 and formulations provided in this disclosure. This extends the
by the methods and compositions of the invention, the organic 60 capability of the invention in delivering otherwise aqueous-
	
phase can include a tracer compound or radiocontrast 	 insoluble drugs.
	
medium to provide the additional advantage of real-time 	 For instance, the use of multiple drugs within the same
	
imaging of the microcapsules with computerized tomography 	 microcapsule provides microcapsules specifically designed
	
(CT) scanning as they are released from the catheter en route 	 for chemoembolization treatments. Multiple-drug microcap-
to the target tissue. Other examples include aqueous soluble 65 sules also may be used to deliver first a chemotherapeutic
	
metallo-organic compounds used for diagnostic imaging 	 drug which kills tumor cells, and then an immuno-adjuvant
	
such as ferrous gluconate or Gadolinium diethylene triamine	 (tumor necrosis factor) or immunological stimulant (e.g.
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interferon-g) that would enhance the patient's immune
response to the tumor. Multiple-drug microcapsules can also
be used to deliver combinations of chemotherapeutic drugs to
tumors that are located in privileged sites, such as brain
tumors. For example, and as described more fully in the
examples to follow, simultaneous delivery of different types
of drugs in the same microcapsule is made possible with the
methods and compositions of the invention, e.g. diaziquone
and cis-platinum to brain tumors via the carotid artery
[Kimier et al. 1993]. Multi-layered microcapsules may also
be used to treat deep infections that are resistant to systemic
antibiotics. In these applications, one or more antibiotics may
be sequentially delivered to the site of the infection. Multi-
layered microcapsules can be designed to protect active forms
of urokinase and other thrombolytic enzymes until they are
delivered and entrapped at the local site of a blood clot, where
therapeutic doses of the enzyme may then be released by
lysing the outer membrane to dissolve the unwanted embo-
lism. The multilamellar microcapsules can also be used to
deliver immunostimulants; cytokines such as Interferons,
Interleukins, and growth factors; antinauseants such as meto-
clopramide and tetrahydrocannabinol; multiple fibrinolytic
enzymes such as urokinase (uPA), tissue plasminogen acti-
vator (tPA) and streptokinase; steroids such as hydrocorti-
sone, dexamethasone, etc.; anti-fungals such as nystatin and
griseofulvin, anti-virals such as amantidine, iododeoxuri-
dine, riboviran; and multiple antibiotics such as amoxicillin,
ampicillin, etc.
In one embodiment, as related to the space-based research
that lead to the Earth-normal embodiments of the invention,
exposure to microgravity for at least 20 seconds in duration
produced microcapsules. If the microcapsules of the inven-
tion are to be used in I-g environments, as is generally antici-
pated, an additional step comprising recovering the multi-
layer microcapsules will be necessarily accomplished at
Earth-normal gravity. Generally, this step will be accom-
plished by reentry and recovery of the orbital device by which
exposure to 0-g was accomplished. While it is preferred to
accomplish the recovery without exposure of the formed
microcapsules to physical extremes (pressure, temperature,
shearing, mixing, etc.), recovery of the microcapsules of the
invention have been accomplished via a transition from
microgravity to Earth-normal gravity at accelerations of at
least 15-g without substantial loss of integrity.
As used herein the term contain or contained in a micro-
capsule or in a liquid phase or layer is construed to have its
normal meaning, and may include suspended or dissolved as
in a liquid layer, or interface, and also includes the meaning
associated with a polymer shell including on its inner or outer
surfaces. As used herein, the term "prodrug" or "proenzyme"
includes the meaning of a precursor, such as intraglandular
prohormones, or the meaning of an agent whose drug or
enzymatic activity, or pharmacological action, results from a
conversion or transformation into an active or more active
form. Such conversion may be the result of a metabolic pro-
cess or biotransformation, or it may be the result of an artifi-
cial reaction.
BRIEF DESCRIPTION OF THE DRAWINGS
For a detailed description of a preferred embodiment of the
invention, reference will now be made to the accompanying
drawings wherein:
FIG. lA Schematic of microcapsules containing magnetic
particle that is heated by exposure to an electromagnetic field.
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FIG. 1B Schematic of microcapsules after magnetic par-
ticle has melted a pore in the outer membrane and interior
contents are diffusing from microcapsule.
FIG. 2 Graph showing the permeability vs temperature of
5 the ceramic ferromagnetic particles encapsulated in the
microcapsules demonstrating a Curie temperature of about
48° C.
DETAILED DESCRIPTION OF THE PREFERRED
10	 EMBODIMENTS
The present disclosure is drawn to multi-layered microcap-
sules and methods of making microcapsules having a poly-
meric outer membrane that may enclose immiscible liquid
15 phases that contain drugs or bioactive chemicals and mag-
netic solid particles that can absorb electromagnetic energy
and thereby heat up to a predetermined temperature (Curie
point or Curie temperature), which is sufficient to melt a hole
in, or to melt at least a portion of, or otherwise lyse the
20 polymeric shell and release the liquid contents of the micro-
capsule including the drug or bioactive chemical. The micro-
capsules described herein may, in certain embodiments be
injected into arteries leading to thrombi, vascularized tumors,
or other capillary beds, or they may be injected directly into
25 tumors or other tissues in order to reach a target site. When the
microcapsules are at the target site, the patient or subject may
be exposed to an external, or internal electromagnetic field,
typically for a period of a few minutes, thereby causing the
magnetic particles to reach their Curie temperature and melt
30 the polymeric shell and release the drug at the target site. In
certain embodiments, multiple releases of drug may be
achieved by including microcapsules containing magnetic
particles with differing Curie points. In addition, these micro-
capsules may also contain different drugs so that sequential
35 administrations of a combination of drugs may be achieved
by manipulating the frequency of the external field and the
length of exposure. The use of magnetic particles for con-
trolled drug delivery may be used with any of the microcap-
sules and delivery methods as described herein and in related
4o applications.
The microcapsules described herein provide advantages
over prior compositions and methods in that the microcap-
sules may be designed to that the Curie temperature is from
about 41° C. to any temperature, even as high as 95° C.
45 without causing widespread thermal damage to local tissues.
Based on the small size relative to a cell and the small number
of particles, collateral damage will be minimal. In addition,
the microcapsules may be used to deliver multiple drugs from
a single administration, or to release several pulses of drug as
50 the case may be. Another advantage is that the drug releases
are triggered by external electromagnetic fields that are non-
invasive, can be applied for a shorter time than is necessary
for tissue hyperthermia, and do not rely on local hyperther-
mia, which is hard to control and may cause collateral dam-
55 age. In addition, induction heating of the magnetic particles is
not restricted to frequencies and power densities normally
needed to induce hyperthermia. The microcapsules are also
useful for storing unstable drugs for extended periods, possi-
bly in an inactive form, and for carrying drugs or bioactive
60 agents to the target site in a protected environment until they
are released, thus avoiding unwanted drug activity at non-
specific sites, as well as avoiding potential problems with an
immune response to the agent. Finally, the microcapsules
containing magnetic particles can be separated and purified
65 using DC magnetic fields and routine separation techniques,
and they can be concentrated in a chosen tissue location by
application of an external magnetic field.
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For those embodiments described herein in which an elec-
tromagnetic field is used to heat microparticles, field strength
may be described alternatively as typically on the order of
85-95 KHz or 1500-2400 A/m, or as approximately 3-5 KW.
It is known that microparticles and microcapsules may be
made to absorb other types of energy than an electromagnetic
field. In certain embodiments the microcapsules may contain
microparticles or internal components that specifically
absorb radiofrequency (6.7-27.1 MHz) or 915-2450 MHz
microwave radiation, or ultrasonic waves at greater than 18
KHz, such that the microparticles or internal components are
heated to a temperature above the melting temperature of the
outer membrane. More specifically, the microcapsules are
designed so that, for a particular type of energy to be used
(e.g., electromagnetic, radiofrequency, microwave or ultra-
sound), the specific absorption rate (SAR) of a microparticle
or internal component is much greater than the SAR of the
outer membrane, which is much greater than the SAR of the
surrounding tissue. The design of such microcapsules is
described in more detail in the Examples below.
The present disclosure provides methods of encapsulating
multiple drugs or biological therapeutics into liquid micro-
capsules or liposomes that are designed for delivery to
selected tissues or organs where, upon activation, a short-
lived drug can be released directly to the target area by diffu-
sion out of the microcapsules. A method of the present dis-
closure may be used to form multi-lamellar microcapsules
having alternating hydrophilic and hydrophobic liquid layers
surrounded by a flexible, semi-permeable, polymeric outer
"skin." In this embodiment, the outer skin is designed to allow
sustained diffusion of the bioactive drug from the microcap-
sule.
The methods and compositions of the present invention
may use special formulations of solubilized drugs, surfac-
tants, polymeric co-surfactants, and energy absorbing com-
ponents within a specific immiscible liquid phase. The energy
absorbing medium (e.g. photo activator, thermoabsorber,
etc.) absorbs electromagnetic, ultraviolet (UV), infrared (IR),
ultrasonic, radiofrequency (RF), or microwave radiation and
thereby causes chemical activation of a chemical substrate or
drug precursor into a bioactive drug molecule which can
readily diffuse out of the microcapsule. The absorbed energy
also can beusedto create thermal convection, Maragoni flows
or other high velocity flows that can cause interfacial mixing,
redistribution of partitioning compartments within immis-
cible phases, and increased radiocontrast of selected compo-
nents within certain liquid compartments. This is exemplified
by UV (220-390 nanometers) photoactivation of microcap-
sules containing drugs, fluorescent compounds and radiocon-
trast media in the same microcapsule. The in situ activated
microcapsules are characterized by: outer polymeric mem-
branes that are both transparent to the activating radiations
and are permeable to the bioactive drug thereby allowing
sustained time-release of the active drug; immiscible fluid
compartments inside the microcapsules or internal spheroids
surrounded by thermosensitive or a shear sensitive interfacial
boundary or membrane, containing chemical components
that absorb the activating energy; chemical reactions or con-
vective mixing that convert the prodrug or proenzyme to the
bioactive form or change the molecular form of a drug (which
is already bioactive) to increase its diffusion rate out of the
microcapsule or its bioavailability once it has been released;
and a longer shelf-life than that of the bioactive drug dis-
solved or suspended in the carrier solution. In the practice of
the invention, one may expose the microcapsules to a first
form of energy or wavelength in order to cause mixing of
immiscible layers or to otherwise activate a prodrug or chemi-
cal agent, and subsequently expose the microcapsules to an
electromagnetic field designed to heat the microparticles and
release the contents of the microcapsules.
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Included within the present disclosure are multi-layered
liquid microcapsules and methods of forming the multi-lay-
ered liquid microcapsules comprising a drug permeable outer
skin or membrane surrounding a sphere of immiscible fluid
5 compartments. The immiscible compartments may contain a
drug precursor in one phase and an activating agent in another
phase. The activating agent may be activated by exposure to
external electromagnetic radiation or other forms of activat-
ing energy causing it to react with the drug precursor to
10 produce an active drug or agent.
Embodiments of the present invention include methods of
exposing the microcapsules to activating radiation or other
forms of activating energy. These methods include, but are
not limited to the following:
15 Direct exposure of the microcapsules in dry or liquid dis-
persion just prior to dispensing. This method may be accom-
plished, for example, by exposure to radiation from a band
pass filter system, laser light, infrared light, radio waves or
microwaves, or a combination of same, all of which are trans-
mitted through the outer membrane of the microcapsules to
20 be absorbed by the activating agent which has been co-en-
capsulated with the precursor drug.
Entrapment of the microcapsules in tissue followed by
external administration of the activating energy through the
skin and outer tissues of a subject without physiological dam-
25 age and absorption of the energy by the activating agent
within the microcapsules, or by magnetic particles resulting
in heating and melting of the polymer outer membrane.
Entrapment of microcapsules in arterioles, venules, or tis-
sues, followed by exposure of the microcapsules via intravas-
30 cular catheters, or other internal devices containing a fiber
optic probe, electromagnetic transducer, or other miniature
energy transducer that can transmit the activating energy
locally to the entrapped microcapsules, again followed by
heating of the magnetic particles to release the activated con-
35 tents.
In the practice of certain embodiments of the inventions,
the absorption of the activating energy may result in a chemi-
cal reaction between an activator and a prodrug or enzyme
precursor that produces a bioactive molecular moiety, or such
absorption may drive fluid mixing and turbulent fluid flows
40 wherein the internal mixing of the immiscible internal phase
containing the prodrug and the internal phase containing the
activator results in production of the bioactive form of the
drug. Alternatively, absorption of activating energy may
occur inside inner spheroids surrounded by a thermosensitive
45 membrane containing a solution of the activating agent where
energy deposition increases the temperature in the spheroid
causing the thermosensitive membrane to rupture or dissolve,
allowing the activating solution to mix with the next outer
solution containing the prodrug or substrate to produce the
50 active agent. Such mixing may also be caused by ultrasonic
radiation, which would be effective to lyse the inner sphe-
roids. The activating energy may also be absorbed by the
outer membrane of the microcapsules, to produce an agent
such as free radicals, superoxides, oxidizing or reducing
55 agents to activate a prodrug.An embodiment of the present invention is also microcap-
sules in which activating energy is absorbed by radiocontrast
media contained in the microcapsules, thus increasing the
radio-opacity of the media while the microcapsules are
trapped in tissue. Examples of such radiocontrast media
60 include, but are not limited to halogenated oils such as halo-
genated poppy seed oil, cotton seed oil, soybean oil, safflower
oil, corn oil, sesame seed oil, canola oil, and others that can be
readily iodinated to produce a radio-opaque contrast medium
for radiographic imaging.
65 For the purposes of this disclosure, the terms "a", "an" and
"one" encompass the conventional meaning, and includes the
meaning "one or more." Hence, a description of a microcap-
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sule, or a pro-drug, for example, would include the meaning
one, or one or more, as a particular context requires.
Thermoparticle Temperature Regulation
At high frequencies, the heating of ferromagnetic metal
rods or particles by electromagnetic induction is mainly due
to eddy currents that are known to circulate almost exclu-
sively in a thin surface layer. Under such conditions, the
power into the thermoparticles per unit length in an alternat-
ing magnetic field, which is applied parallel to the long axis,
is:
Pe_.(po,pfl iizaH2
where Pe is the power input due to eddy currents, W/m; µ o is
the permeability of free space, 47tx10 -7 Wb/A•m; µ is the
relative permeability of the thermoparticle, dimensionless; p
is the electrical resistivity, ohm-m; a is the radius of the
then noparticle, m; H is the amplitude of the sinusoidally,
varying magnetic field, A-m; and f is the frequency, s - '  (Chen
et al., 1988). From this equation, the only material properties
that affect the power input to a heating thermoparticle are µ
and p; H and f are characteristics of the induction heating
equipment and its operating conditions. Resistivity does not
change appreciably at the Curie temperature, and the varia-
tion of resistivity in the temperature range just below the
Curie temperature is small compared to the corresponding
change in permeability. More importantly there is a drastic
reduction in the relative permeability as the temperature
closely approaches the Curie temperature and this results in a
corresponding reduction in the power absorption, current
flow, and subsequent heating.
FIG. lA is a schematic drawing of a drug or enzyme
contained in a microcapsule that also contains a metal particle
or sphere, such as a ferromagnetic ceramic particle, for
example. The microcapsule 120 has an outer polymer mem-
brane 122 that encloses one or more internal liquid phases
124,128. In the embodiment shown in the figure, two internal
liquid phases are shown. In the embodiment shown, a first
internal phase 128 contains a drug or enzyme 130 for which
the membrane 122 is impermeable. A second internal phase
124 may, in certain embodiments, contain an activating agent
141. A metal particle 136 contained in the microcapsule 120,
has a Curie temperature higher than the melting point of the
outer membrane 122. An activating electromagnetic field 132
is shown passing through the outer membrane 122 and caus-
ing the metal particle 136 to heat and to melt a hole or pore in
the outer membrane 122. In various embodiments of the
invention, the internal liquid layer adjacent the outer mem-
brane 122 and that contains the magnetic particle 136 may be
an aqueous layer or a hydrocarbon layer depending on the
solubility of the active drug. The magnetic material used in
microcapsules as described herein is also typically coveredby
a coating 140 such as a ceramic that is compatible with the
liquids within the microcapsule and with the drug or active
agent. Although the particles described herein are coated with
ceramics, other coatings that are compatible with the liquid
phases and drugs or solvents to be used in the microcapsules.
Ceramics were chosen for the exemplary microcapsules
described below because of their low antigenicity, they are
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not chemically reactive with the solvents or drugs used in the
microcapsules, and the protect the metal from oxidation.
Alternate coatings would include, but not be limited to meth-
acrylates, alginates, dextran, polyacrylates, polyvinyl pyr-
5 rolidone (if the ferrous material is fully oxidized).
FIG. 1B is a schematic drawing of a portion of a microcap-
sule shown in FIG. lA after the metal particle 136 has melted
a permanent hole or pore 138 in the outer membrane 122. The
10 
pore 138 allows the contents of the microcapsule 120 to leak
out, including any drug 130 that is contained in an internal
liquid phase 128 next to the outer membrane 122.
FIG. 2 is a graph showing the permeability vs temperature
of the ceramic ferromagnetic particles encapsulated in the
15 microcapsules described in Example XI. The Curie tempera-
ture is shown to be about 48° C.
A series of more than 38 separate experiments on four
space flights has led to the development of aspects of this
invention. These experiments along with their ground-based
20 counterparts are described below for the purpose of pointing
out the invention specifically and providing details useful in
carrying out the invention. These specific examples, however,
do not limit the scope of the claimed invention.
The following examples are offered by way of illustration
25 and are not intended to limit the scope of the invention in any
manner. All of the materials used in these examples were
obtained from well known commercial sources, or as specifi-
cally stated in the examples. Essentially conventional meth-
ods were employed in each instance where no specific pro-
30 cedure is stated.
Example I
Microgravity Experiments Summary
35
The basic formulations and simplified liquid-liquid, dis-
persion methods were developed in 1988 and 1989. The basic
concept is the formation of a multi-lamellar microcapsule
with an aqueous drug/oil dispersion at its center, a hydrocar-
40 bon/oil drug#2 and/or radiocontrast medium (e.g. IPO) as a
next layer, an aqueous layer/drug (e.g., cis-platinum) as a next
layer, and a polymeric outer coating or skin. Microencapsu-
lation-related experiments designed to overcome the limita-
tions of the first methods were conducted on six space mis-
45 sions beginning in April 1989 with the Consort-I sounding
rocket using the Materials Dispersion Apparatus (MDA)
mini-lab developed by Instrumentation Technology Associ-
ates, Inc. The sounding rocket flights produced only 6.5 min-
utes of microgravity conditions, but this was adequate to form
50 the unique microcapsules in a single step. Experiments on the
Space Shuttle permitted 10 minute dispersion times followed
by curing of the outer polyglyceride skin for eight days under
microgravity conditions. A summary of these experiments is
shown in Table 2. New formulations were tested on Shuttle
55 STS-52, using only aqueous-soluble drugs, polymers and
surfactants, and on STS-56 using alcohols as co-surfactants.
The specific experiments and results are described in detail in
the examples to follow.
TABLE 2
MED Flight Experiments Summary
MISSION DATE	 EXPERIMENTS MATERIALS 	 RESULTS
Consort-1 April 1989	 protein diffusion	 urokinase & antibodies diffusion rates established
Consort-1 March 1990	 diffusion kinetics	 urokinase & myoglobin kinetics verified
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TABLE 2-continued
MED Flight Experiments Summary
MISSION DATE	 EXPERIMENTS MATERIALS RESULTS
Consort-4	 November 1991 microencapsulation Cis-Platinum, multi-lamellar microspheres w/
of drugs" amoxicillin, urokinase alternating hydrophilic &
& Streptavidin hydrophobic layers
Consort-5	 September 1992 microencapsulation Cis-platinum, multi-lamellar microspheres w/
of drugsab amoxicillin & alternating hydrophilic &
urokinase hydrophobic layers
STS-52	 October 1992	 microencapsulation Cis-platinum, multi-lamellar microspheres,
of drugs (aqueous amoxicillin & crystals within microcapsules
polymers only)ab urokinase
STS-56	 April 1993	 microencapsulation Cis-platinum, multi-lamellar microspheres,
of drugs (alcohol amoxicillin & crystals within microcapsules
co-surfactants) ab urokinase
30
'Fluorescent labels included
bFluorescent beads included
Example II
	
	 20 labels were used to determine the distribution of drug in the
various fluid compartments. Additional experiments, con-
Gravity-Dependent Restrictions Recognized
	
	
ducted on Consort-5 in September 1992, confirmed the capa-
bilities of the new method for forming multi-lamellar micro-
Gravity-dependent restrictions in the basic liquid-liquid 	 capsules with alternating layers of hydrophilic and
spontaneous microencapsulation process led to the design of 25 hydrophobic drugs.
several microgravity experiments to explore the utility of this 	 Microcapsules formed in 38 microgravity mini-experi-
process when density-driven phenomena were eliminated. In 	 ments used liquid-liquid dispersion of aqueous drug solu-
particular, density-driven, gravity-dependent restrictions of	 tions, surfactant and polyethylene glycol dispersed in alco-
the liquid-liquid microencapsulation process were: early 	 holic	 co-surfactant	 solutions	 containing	 soluble
phase separation producing fragile microcapsules; interfacial 30 polyglycerides.
dynamic flow causing coalescence of microcapsules. Failure 	 Microcapsules of both oil/water and polymer/water/oil
of ground-based experiments to derive uniform microcap- 	 were recovered from the Consort flights. These experiments
sules lead to a desire to attempt microcapsule formation in 	 produced multi-lamellar liquid microcapsules (concentric
space.	 spheres within spheres) comprised of three or more, alternat-
The microgravity flight experiments led to the develop- 35 ing immiscible layers. Image analysis of the microcapsules
ment of a new liquid-liquid microencapsulation process that 	 was made possible by co-encapsulation of standard size fluo-
involves use of surfactants and co-surfactants in the aqueous	 rescent beads. Microcapsules were formed in the ranges of
phase and co-surfactant alcohols in the organic phase, which
	 1-15 microns, 40-50 microns, 110-130 microns and 160-230
also contained, in one embodiment, high molecular weight 	 microns in diameters. This was a substantial improvement
polymers that formed a tough outer "skin" on the final micro- 40 over the prior art approaches which had initially been
capsules. In microgravity, a single step dispersion produced 	 attemptedby the inventors to derive microcapsules only in the
unique multi-lamellar microcapsules containing various 	 10 micron and less range. The size distribution covered a
aqueous drugs co-encapsulated with iodinated poppy seed oil	 range of from about as low as 5 microns in diameter up to
(a radiocontrast medium with a sp. gravity=1.35). Subse-	 about 300 microns in diameter and greater. The average size
quent ground control experiments also produced some of 45 of the microcapsules formed in these experiments was about
these unique microcapsules and illustrated that the 1-g pro- 	 150 microns, greatly in excess of the average 10 micron or
cess could be improved to yield useable microcapsules by 	 less diameters obtained with prior art approaches.
using different formulations. In particular, it became clear 	 The ruggedness of the microcapsules formed under these
that the outer coatings substantially improved the ruggedness	 conditions allowed for size segregation by filtration or other
of the microcapsules formed. 	 50 separation methods. Digital image analysis (National Insti-
tutes of Health image analysis program) of phase contrast and
Example III
	
fluorescent images taken with a fluorescent microscope also
confirmed that the aqueous-soluble drugs were routinely
Sounding Rocket Experiments 	 encapsulated within the inner aqueous core and the outermost
55 aqueous shell of the microcapsules.
Initial experiments on Consort-1 and -3 were used to deter-	 Multi-lamellar microcapsules were, also formed which
mine the effective mixing and diffusion kinetics in the MDAs 	 contained relatively large amounts of IPO (Guerbet Labora-
(see below for apparatus description). This showed that suf-	 tories—France, Savage Laboratories U.S.A.) in discrete
ficient volume was mixed at the interface via diffusion to 	 lamella, including microcapsules heavily loaded with IPO,
allow formation of microcapsules. These experiments also 60 which often comprises up to 38% of the total volume. Often
provided the diffusion constants for each of the components 	 small hemispheres of IPO were also found clinging to the
of the liquid phases.	 outer surface of the large inner (aqueous) sphere or adhered to
The first successful microencapsulation of drugs in micro- 	 the outer polymer skin of the microcapsule.
gravity was conducted on the Consort-4 mission in November	 Microcapsules formed by almost all of the formulations
1991. The microcapsules were recovered and analyzed by 65 survived 15-g accelerations, severe vibrations and turbulent
microscopic image analysis. Mono-dispersed fluorescent	 mixing, during the reentry of the experiment capsule, and
beads were included as internal size standards and fluorescent 	 have remained intact for two years after recovery from space.
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These multi-layered microcapsules are similar to liquid-
filled, thin-skinned, micro-balloons which are flexible
enough to be manipulated on a microscope slide without
collapse.
The microcapsules formed in just 6.5 minutes of micro-
gravity retain their spherical shape and appear tough enough
to survive the extensive physical manipulations required for
sizing, final preparation and storage of parenteral suspen-
sions, and the fluid shear encountered after intravascular
injection. The inventors have also discovered that such cap-
sules may form within a period of a few seconds.
Also formed were very unusual structures (multiple small
spheres of aqueous-soluble drug) distributed within multi-
lamellar o/w/o microcapsules, whereinthe aqueous spheroids
are arranged in an annular ring that appears fixed in a plane
within the innermost sphere. These ring structures remain
intact when the microcapsules are "rolled around" on the
microscope slide without rupturing. These structures demon-
strate the ability of the methods of the invention to form small
spheroids that do not coalesce inside the larger microcapsule.
Such structures may be advantageously used to control the
specific volume to surface area ratio in order to control the
rate of diffusion of a solute in such spheroids. In particular,
sustained release of pharmaceuticals contained in such sphe-
roids within microcapsules may find utility, as will applica-
tions in which the contents of such spheroids may be released
into the microcapsule by ultrasonic irradiation.
Example IV
Space Shuttle Experiments
In experiments conducted on STS-52, the inventors co-
encapsulated cis-platinum (diaminodichlor-cis-platinum;
Bristol Laboratories) with IPO by forming microcapsules
from water-soluble polymers using special formulations of
aqueous, non-alcoholic solvents. Such formulations will find
particular utility in co-encapsulations of anti-tumor com-
pounds along with radiocontrast medium for tracking drugs
in the body.
Polyvinyl pyrolidone (PVP), polyvinyl alcohol, and a com-
mercial lecithin (Centrolex-F(k; a phospholipid compound
derived from soya and produced by U.S. Soya, Inc.) were
used to form multi-lamellar microcapsules at 20° C. Fluores-
cent beads and fluorescent label were co-encapsulated with
the drugs to permit drug-distribution measurements within
the various lamellae, using fluorescence microscopy and digi-
tal image analysis. The final microcapsules were recovered
and resuspended in either aqueous solutions, IPO or mineral
oil. The microcapsules formed by these formulations were
similar to those made using alcohol-soluble polyglycerides.
However, without the hydrocarbon-soluble polymer mem-
brane these microcapsules were more fragile and friable.
Another unique type of microcapsule was formed during
these experiments that was characterized by drug crystals
formed within the inner aqueous core of the multi-lamellar
microcapsules. Microcapsules were formed which were
packed (approximately 65% of the aqueous compartment)
with crystals of Cis-platinum, an anti-tumor drug. Microcap-
sules containing crystals of amoxicillin were also formed in
the STS-52 experiments. These illustrate that aqueous-
soluble drugs can be encapsulated at very high concentrations
near the solubility limit of the drug. After the microcapsules
are formed the drug can become further concentrated (per-
haps via the alcohol absorbing the water from the aqueous
phase in which the pharmaceutical solute is dissolved) to
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form large crystals which are more stable than the dissolved
drug during prolonged storage.
Microcapsules formed from first organic solvent/polymer
methods appeared to be more rugged (by visual comparison
5 under the microscope) than those formed on STS-52 formed
from first solvent aqueous/polymer methods. The STS-56
experiments again produced multi-lamellar liquid microcap-
sules (multiple concentric spheres within spheres) comprised
of alternating immiscible layers. Using fluorescent 6.4
io micron beads and image analysis, it was found that the most
interesting microcapsules were formed in the range of 10-15
micron, 40-50 micron, 50-100 micron, and 160-230 micron
diameters. These diameter distributions were of particular
interest since it is known that intraarterial uses can accom-
15 modate 50-300 micron diameter microcapsules while intra-
venous applications can only tolerate 1-10 micron microcap-
sules. Thus, by segregating the microcapsules into sized
fractions (sieving), it is possible to address particular intra-
vascular limitations.
20 As noted above, microcapsules were formed containing
crystals of cis-Platinum or amoxicillin. The crystals appar-
ently were formed after encapsulation. Several microcapsules
were formed that contained a single, large cubic crystal of
Cis-Platinum which so completely filled the inner sphere that
25 only about l5%oftheinnervolume remained asa liquid. One
encapsulated, cubic Cis-Platinum crystal was measured at 48
microns across within a 57 micron diameter microcapsule.
After formation, some of the microcapsules were dispersed in
an external oil phase (either IPO or mineral oil) and allowed
30 to cure for eight days before return to Earth.
These microgravity experiments have shown that forma-
tion of multi-lamellar, alternating-phase microcapsules can
be controlled by proper timed-sequence exposures of the
immiscible phases using special solvent formulations and
35 surfactants. Once formed, these microcapsules remain
spherical due to the predominant surface tension of the inter-
nal phases and polymer/solvent phase partitioning at the
interfaces.
These experiments clearly demonstrated the capability to
40 use liquid-liquid diffusion mixing to form unique microcap-
sules containing hydrophilic and hydrophobic drugs under
microgravity conditions. Thus, ground-based experiments
were conducted to compliment and replicate the space experi-
ments. These ground-based experiments were able to repli-
45 cate the size range (5-250 microns in diameter) to a limited
degree, but the average size microcapsule obtained was about
10-40 microns in diameter. Still, this was a substantial
improvement over the prior art approaches which rarely
formed microcapsules over 10 microns in diameter. It was
5o also observed that the ground-based experiments resulted in
less rugged microcapsules. This is likely a result of the grav-
ity-dependent deformations of the spherical microcapsules as
they form giving rise to areas of thinner polymer deposition.
Thus, the flexible microcapsules, formed under micro-gravity
55 conditions, were of more uniform size distributions than
those formed in 1-g, were more rugged, and had a higher
average diameter than ground-made microcapsules, largely
due to the absence of thermal convection, buoyancy forces,
and instabilities that occur at the immiscible interfaces. These
60 problems have been largely overcome by new manufacturing
apparatus as described in a related application, "Microencap-
sulation and Electrostatic Processing Device" invented by
Dennis R. Morrison, Benjamin Mosier and John M. Cas Santo,
incorporated herein by reference.
65 The microgravity experiments illustrate the feasibility of
co-encapsulating aqueous-soluble drugs, hydrocarbon-
soluble drugs and oil-based contrast media within a lipid-
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soluble, polyglyceride outer film which cures rapidly enough
	
liquid diffusion methods also could be used for encapsulating
to be impervious to oil or hydrocarbon resolubilization. They 	 certain labile drugs to make microcapsules for special pur-
also allow the formation and harvesting of unique microcap- 	 pose drug delivery systems, especially those designed to
sules which are durable enough to be removed from the	 deliver drugs via the nasal or buccal mucosa or via inhalation
external solvent without disruption or destruction of the inter- 5 directly to the lungs. Examples include protected delivery of
nal phases. It is anticipated that these microcapsules will have 	 mucolytic DNAse for sustained release treatment of cystic
several advantages over conventional liposomes that are 	 fibrosis and I anti-trypsin for patients with deficiencies in the
designed for intravascular injection.	 lung epithelium.
Example V	 10	 Example VII
Flight Hardware Description	 Redispersion of Microcapsules in Aqueous or Oil
Vehicles
The microencapsulation experiments described herein
were conducted using the Materials Dispersion Apparatus 15	 A frequently used second step includes dispersion of the
(MDA; ITA, Inc., Exton, Pa.). The MDA's consist of an upper 	 microcapsules (after they have formed) in different aqueous/
and a lower block that contain chambers for each sample 	 polymer solvents or in a pure oil phase. A unique attribute of
fluid. The blocks are misaligned at launch so that the cham- 	 microcapsules formed by these methods is that they do not
bers are not in contact with each other. Upon activation in 	 re-dissolve in an oily external phase, even though the semi-
microgravity, the blocks are moved to align the chambers so 20 permeable outer skin is hydrophobic. This produces a sus-
that the fluids can mix by liquid-liquid diffusion. Some of the	 pension in the liquid carriers that are commonly used for
experiments were conducted with a single-step fluid mixing,	 intravascular administration.
and some were done with a two-step fluid mixing technique 	 Examples of suitable aqueous solutions for redispersion
which allows diffusion of a third fluid or sample into the 	 would include, but not be limited to dextran, PEG, phosphate
mixture of the first two fluids while still in the microgravity 25 buffered saline (PBS), Ringer's solution, or any solution
environment. In these experiments, the shear forces are mini- 	 known in the art that is selected so the membrane has little or
mal while moving the fluids into contact with each other. 	 no solubility in that medium. The solutions are sterilizedprior
to redispersion and are selected for the particular application,
Example VI	 such as injection into a human. It is a further advantage, that
30 redispersion in these solutions inhibits coalescence.
Discussion and Alternative Embodiments
Example VIII
Spontaneous formation of multi-lamellar, microcapsules
containing alternating layers of aqueous and hydrophobic 	 Exemplary First Organic Solvent Microcapsule
solvent compartments is strongly dependent on the interfacial 35	 Formulations
tension and the amount of mixing between immiscible liquid
phases. On Earth this process is limitedby gravity-dependent,	 The following formulations have been used with particular
density-driven separation of the immiscible liquids into 	 success by the inventors in both Earth-normal and micrograv-
stratified horizontal layers. In microgravity, this process is 	 ity methods of making microcapsules.
largely dependent on the surface-free energies of the different 40	 Fluid 1 (hydrocarbon). The first solvent is a hydrocarbon
liquids, but independent of density-driven convection or 	 fluid (ethyl alcohol, methyl alcohol, or isopropyl alcohol)
buoyant phase separation. Hydrocarbon soluble, high	 with a low or medium HLB (HLB-5-10). One or more co-
molecular weight polymers have been included in the formu- 	 solvents are used (which also canactas co-surfactants). Small
lations to form flexible, permeable "skins" or outer coatings 	 concentrations of oil and water are added. Into this mixture,
around the liquid microcapsules as they are created by phase 45 the mono- or polyglyceride is dissolved up to 5% w/v.
partitioning mechanisms. It is also possible to form such	 An example is:
polymer barriers between internal layers. The microcapsules 	 88% IPA
can be formed and cured without deformation by contact with 	 2.5% m-Hexanol
container walls. 	 2.5% n-Heptanol
More specifically, co-encapsulation of an aqueous-soluble, 50	 5% IPO
anti-tumor drug (Cis-platinum) and a radio-contrast medium 	 2% H2O
(IPO), in microgravity, has produced a unique drug delivery 	 5% GMS
system that can be visualized by radiologic or computerized	 Fluid 2 (aqueous). The second solvent is waterplus surfac-
tomography scanning to insure that the cytotoxic drug is 	 tants (ex. polyethoxylated sorbitan esters; polyethylene gly-
delivered directly to the target tumor. Multi-layered micro- 55 col). A polysaccharide (Dextran) and normal saline (0.9%)
capsules have been developed which can provide a new intra- 	 are added which helps achieve the desired critical micelle
vascular delivery system for targeted tissues and sequential, 	 concentration. A pharmaceutical soluble in water is added.
sustained and controlled release of multiple anti-tumor drugs. 	 An example is:
This method has resulted in formation of flexible spherical 	 I% PEG 4000
microcapsules of more uniform sizes, which can provide 60 5% Dextran-40 (MW=40,000)
maximum packing densities and maximum drug delivery to	 0.9% Sodium chloride
target organs or tumors.	 2% Sorbitan Monooleate/20 moles Ethylene oxide
Multi-layered microcapsules can be designed to protect 	 Water (up to 100% volume)
active forms of urokinase and other thrombolytic enzymes 	 dissolved drug at specified concentration
until they are delivered and entrapped at the local site of a 65	 (according to required dose and release rate)
blood clot, where therapeutic doses of the enzyme can diffuse 	 Fluid 3 (oil). An oil, immiscible with the first two fluids in
out to dissolve the unwanted embolism. These immiscible-	 which the microcapsule's "outer skin" is insoluble so that the
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suspended microcapsules can be delivered by injection when
non-aqueous administration is required. Submersion of
microcapsules in the oil also can aid the curing or polymer-
ization of the "outer skin." A preferred example of the oil
vehicle is halogenated poppy seed oil which also serves as a
radiocontrast medium.
Alternate Compositions for Fluid 1
Main solvent—ethyl alcohol
Co-solvents—(co-surfactants) are normal alcohols--C4 to
C8
high dielectric constant solvents
tetrahydrofuran
dioxane
acetonitrile
dimethylformamide
dimethylacetamide
dimethylsulfoxide
Oil—dense radiocontrast liquids s.a. halogenated unsatur-
ated oils
e.g. halogenated poppy seed oil, cotton seed oil, safflower
oil, olive oil, canola oil, peanut oil, sesame oil, corn oil.
also saturated oils can be used, s.a. heavy mineral oil, liquid
petrolatum
Polymers used to form the "outer skin" on the microcap-
sules
Monoglycerides, polyglycerides, esp. glycerol esters
ranging from C12-C22,
e.g. monostearate, distearates, monooleates, monolau-
rates and olive oil
polyglycerides- cholesterol, waxy plant sterols (stigmas-
terol, phytosterol, campesterol)
phospholipids lecithins (phosphatydyl choline) and/or
combinations with mono/polyglycerides
polyvinylpyrolidone
polyacrylates,
PEG-hydroxypropyl methacrylate (HPMA)
PEG 4,000-12,000
polyethylene glycol/acrylate copolymers
polyethylene glycol/dextran copolymers
Alternate Concentrations:
Main solvent 75-95%
Co-solvents 1-10%
Gil 1-10%
Polymer 1-5%
Water 1-20%
Alternate Composition for Fluid 2
PEG 400-20000
Dextran (MW=40,000-100,000)
0.9% Sodium chloride
Sorbitan Monolaurate/20 moles Ethylene oxide
balance is water
Drug dissolved at saturated or specified concentration
(according to required dose and release rate)
Alternate Concentrations:
PEG	 1-5%
Dextran (MW = 40,000-100,000)	 5-10%
Sodium chloride	 0.9%
Sorbitan Monolaurate/20ETO	 1-5%
Water (balance of volume)
Drug concentration saturated or specified
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Alternate Composition for Fluid 3 (Oils)
Dense radiocontrast liquids s.a. iodinated unsaturated oils
e.g. poppy seed oil, cotton seed oil, safflower oil, olive oil,
canola oil, peanut oil, sesame oil, corn oil. Also saturated oils
5 can be used, s.a. heavy mineral oil and petrolatum.
One hundred percent oil or a mixture may be used as a
carrier vehicle for the suspended microcapsules
Example IX
10
Exemplary First Aqueous Solvent Microcapsule
Formulations
15 Alternate Method Hydrophilic Outer Skin
Fluid 1-(aqueous); the main solvent is a water, one or
more co-solvents (which also can act as co-surfactants), and a
lecithins are dissolved up to 5% w/v to form the outer skin on
the microcapsules.
20	 An example is: 3% polyvinyl alcohol dissolved
in a mixture of
20% isopropyl alcohol and
80% water
Fluid 2 (aqueous); the main solvent is water plus surfac-
25 tants (ex. polyethoxylated sorbitan esters; polyethylene gly-
col) and plus a polysaccharide (Dextran) and normal saline
(0.9%) which helps achieve the desired critical micelle con-
centration.
An example is: 1% PEG 4000
30 5% Dextran-70 (MW=70,000)
0.9% Sodium chloride
2% Sorbitan Monooleate/20 moles Ethylene oxide
Water (up to 100% volume)
dissolved drug at saturated or specified concentration
35	 (according to required dose and release rate)
Fluid 3 (aqueous) —a PEG and PVP solution which can aid
the curing or polymerization of the "outer skin."
1% Polyvinyl pyrollidone
4% PEG 4000
40 5% Dextran-70 (MW=70,000) balance is 0.9% Sodium
chloride
Example X
45	 Externally Triggered Microcapsules
Multilayered microcapsules were formed in microgravity
conditions, containing cis-platin and ferromagnetic particles
obtained from Ceramic Magnetics, Inc. (Fairfield, N.7.).
5o These ferromagnetic particles (<lµ)are composed of 66 wt%
Fe2O3, 9 wt % NiO and 25 wt % ZnO. These ceramic (mag-
netic) particles have a Curie temperature of about 48° C.
(FIG. 2). The microcapsules ranged from 10 to 100µ in diam-
eter. Microcapsules of this size are suitable for chemoembo-
55 lization of solid vascular tumors such as those in the spleen,
liver, kidney or pancreas, whereby the anti-tumor drug, cis-
platin in the case, can be released by exposure to an externally
triggered electromagnetic field.
For use in pancreatic or liver cancer, for example, the
60 microcapsules described in this example would be infused
into a designated artery or directly injected into the tumor
during a surgical procedure. The patient is subjected to an
electromagnetic field of about 85-100 KHz, or a magnetic
field strength of about 0.1 Tesla for a period of about 10
65 minutes in order to release the drug. In alternate embodi-
ments, one could use an electromagnetic field of from about
20 to about 500 KHz.
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For embodiments using a magnetic field such as described
in this example, the microcapsules are designed so that the
SAR of the microparticle is much greater than that of the
microcapsule membrane and the tissue. Typically the SAR of
the microcapsule is 2 to 4 times greater than the SAR of the
outer membrane, which is 4-10 times greater than the SAR of
the surrounding tissue.
Example XI
Alternative Forms of Energy for Externally
Triggering Microcapsules
The microcapsules described herein may also be designed
to trigger a drug release by application of radiofrequency
(RF). In this case, the microcapsule is designed to have a SAR
for the RE of at least 20 times greater than that of the sur-
rounding tissues. In such applications, the microcapsules may
contain internal components of high dielectric particulates,
such as amorphous carbon, graphite, aluminum powder,
acetylene black, a combination of TWEEN, sodium amyl
alcohol, and paraffin oil, or other metallic particles dispersed
throughout or surrounded by a thin layer of a lower dielectric
medium that is a solid or dense gel, such as polyacrylate,
nylon, or polyethyl methacrylate, for example. The use of
such materials as amorphous carbon, graphite, aluminum
powder, or other metallic particles as absorbers of both
radiofrequency and microwave energy are described in the
literature, in particular in Gautherie, 1990, pages 9-16, Chou,
et al., 1984, and Guy et al., (incorporated herein in pertinent
part by reference). The overall conductivity of the micropar-
ticles contained in the microspheres are at least 5 times
greater than that of surrounding tissues at the wavelength
used. A table of minimum conductivities follows:
TABLE 3
Minimum conductivity of microparticles inside therapeutic capsules.
Frequency	 25
1 MHz	 2.5 MHz	 10 MHz MHz
Conductivity at	 3500	 3100	 4000	 4500
37° C.
(mS/meter)
mS is milli Siemens (amps/vol)
Because the microparticles are more dense than the liquid
contents of the microcapsules, the microparticles sediment to
the membrane. When the radiofrequency is applied, the
microparticles heat much more rapidly than the membrane,
thus melting a hole in the outer membrane. Often two elec-
trodes or two planes of electrodes are used, however, indi-
vidual voltage control for each set of electrodes is normally
required.
In those embodiments in which microwave heating is used,
the typical microwave range is from about 300 MHz to about
300 GHz. Frequencies above 2450 MHz require a shielded
room to avoid interference. The same heating principles apply
as described for radiofrequency, i.e. the SAR of the micro-
particle is much greater than the SAR of the outer membrane,
which is much greater than the SAR of the surrounding tissue.
Spherical microparticles may be used, however, the preferred
shape of the microparticles is a tiny rod or miniature helical
coil to maximize local microwave absorption and punctuate
heating. The primary energy absorber in the microparticles
can be made of carbon fibers, amorphous carbon, graphite
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particles, aluminum, acetylene black, a combination of
TWEEN, sodium amyl alcohol, and paraffin oil, or other
metallic particles surrounded by a ceramic, a polymer, or a
dense gel that has a thermal conductivity at least 5 times
5 greater than that of the polymer comprising the outer mem-
brane of the microcapsule. The preferred mode is to use
frequencies up to 250 GHz or greater where the quarter wave-
length node is on the order of 10 microns, which is the size of
the energy absorbing microparticles.
10 In those embodiments in which ultrasound is used to trig-
ger the microcapsules, microspheroids containing oils or
alcohols and surfactants may be made in the same manner as
the primary microcapsules except that these spheroids are
then coated with a layer of charged polymer that has a con-
15 ductivity on the order of 5000 mS/meter or greater. Several of
these microspheroids are then dispersed inside the drug car-
rying larger microcapsule, the outer membrane of which has
a melting point at least 20° C. less than that of the outer wall
of the ultrasound absorbing microspheroid. As the ultrasound
20 is transmitted through the tissues (and the outer membrane of
the microcapsules), it is absorbed by the different density
phases inside the spheroids. For example, ultrasound is
reflected by the more dense, conductive outer wall and thus
the microspheroid heats up to a temperature above the melt-
25 ing temperature of the outer membrane and thus melts a hole
in the microcapsule outer membrane. Typical components
inside the microspheroid are amyl alcohol, sorbitan
monooleate, SMO-20, oils, and other mediums that have a
density significantly different from that of water (aqueous
30 phases inside the microcapsule) and the surrounding tissues.
The use of oil/graphite and other oil layers for absorption of
ultrasound is described in Gautherie, 1990, pages 92-93,
Madsen et al., 1982, and Lele et al., 1982, (all incorporated in
pertinent part herein by reference.)
35 Thus the system represents an ultrasound absorbing micro-
capsule (microspheroid) made in the same fashion as the
larger microcapsules described herein, but the microsphe-
roids are then placed inside a therapeutic microcapsule with
an outer membrane that melts at a temperature at least 20° C.
4o below that of the microspheroid.
It is also understood that the present methods may be used
in conjunction with other forms of therapy including, but not
limited to hperthermia therapy. The use of the combination
of hperthermia and chemotherapeutic drugs is discussed in
45 Urano et al., Local Hyperthermia in Combination with Che-
motherapeutic Agents, in Interstitial Hyperthermia, L.
Handl-Zeller (ed.) Springer-Uerlag, New York, 1992, incor-
porated in pertinent part herein by reference.
The present invention has been described in terms of par-
50 ticular embodiments found or proposed to comprise preferred
modes for the practice of the invention. It will be appreciated
by those of skill in the art that, in light of the present disclo-
sure, numerous modifications and changes can be made in the
particular embodiments exemplified without departing from
55 the intended scope of the invention. For example, one alter-
nate embodiment includes use of aqueous-soluble cyclodex-
trin (in the hydrophilic phase) which has a hydrophobic center
that can itself entrap hydrophobic drugs thereby acting as a
carrier for hydrophobic drugs within the aqueous phase.
6o Another alternate embodiment allows after microcapsules are
formed, for ancillary polymeric outer coats to be applied by
conventional methods (electrostatic coating, aerosolization
and drying, etc.). This is made possible by designing the
precise chemical makeup of the initial polymeric outer skin
65 such that it will be compatible with both drug diffusion and
the ancillary coating to be applied. When surfactants are used
to facilitate adhesion of the third solution or ancillary coating
US 7,968,117 B1
39
the HLB must be selected to be compatible with the HLB of
the existing outer coating which has already been formed,
such that the solution containing the ancillary coating will
wet the surface of the existing outer coating, to enable depo-
sition of the ancillary coating. This is in contrast to conven- 5
tional liposomes whose outer membrane composition is a
variable, depending on the phase separation of the phospho-
lipids and cholesterol adduct when each liposome forms.
Another alternative embodiment incorporates an energy
absorbing medium (e.g. photoactivator) which can absorb 10
electromagnetic, ultraviolet, infrared, ultrasonic, radiofre-
quency and microwave radiation and thereby cause activation
of a short-lived drug component just prior to administration or
after the microcapsules have reached the target site. Another
embodiment incorporates magnetic particles and magnetic 15
fields or free-fluid electrophoretic mechanisms, etc. to facili-
tate dispersion or transport of one phase across the immis-
cible interface into the other phase. This has been demon-
strated as a single pass, unidirectional form of mixing that is
best exploited in microgravity. Another embodiment includes 20
attachment of certain (hydrophobic) antibodies to the poly-
meric skin which gives the microcapsules site specificity by
being able to bind to target cells (e.g. tumor) while entrapped
drugs diffuse out to provide maximum doses to those cells
with that antigenic site. Another embodiment makes use of 25
polyethylene glycol (PEG) complexed to peptide or protein
drugs and a customized polymeric outer skin which permits
the drug-PEG complex to diffuse out of the microcapsule as
an intact entity. This permits the drug to resist antibody
attachment and remain in the blood stream longer as found in 30
the Pegnology 4 type of drug complexes developed by Enzon,
Inc. The improvement being delivery of this complex in the
tailored microcapsules and controlled release of the complex
through the specially designed polymeric outer skin. Another
embodiment is microcapsules containing magnetic particles 35
that can be heated by exposure to an electromagnetic field so
that the particles are able to melt the polymer shell and release
the contents without causing widespread hyperthermic dam-
age to the surrounding tissues. Other embodiments include
the use of the microcapsules of the invention for the produc- 40
tion of crystals within an internal aqueous phase. All such
modifications are intended to be included within the scope of
the appended claims.
While the preferred embodiments of the invention have
been shown and described, modifications thereof can be made 45
by one skilled in the art without departing from the spirit and
teachings of the inventions. The embodiments described
herein are exemplary only, and are not limiting. Many varia-
tions and modifications of the invention and apparatus dis-
closed herein are possible and are within the scope of the 50
inventions. Accordingly, the scope of protection is not limited
by the description set out above, but is only limited by the
claims which follow, that scope including all equivalents of
the subject matter of the claims.
All patents and publications mentioned in this specification 55
are indicative of the level of skill of those of knowledge in the
art to which the invention pertains. All patents and publica-
tions referred to in this application are incorporated herein by
reference to the same extent as if each was specifically indi-
cated as being incorporated by reference and to the extent that 60
they provide materials and methods not specifically shown.
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capsules forArterial Chemoembolization: Appearance and
	
immiscible liquid phases comprising the steps of:
	
In Vitro Drug Release Characteristics, J. Microencapsula- 	 providing one or more microcapsules comprised of:
tion 5:13-20, 1988.	 10	 the one or more immiscible liquid phases, wherein the
What is claimed is: 	 liquid phases are comprised of at least one aqueous
1. A method of controlling the release of a plurality of 	 phase and at least one hydrocarbon phase;
immiscible liquids comprising the steps of: 	 a flexible polymer outer membrane encapsulating the
	
providing one or more microcapsules wherein the one or	 one or more liquid phases, the polymer outer mem-
more microcapsules comprise: 	 15	 bran having a melting temperature; and
the plurality of immiscible liquids;	 one or more energy absorbing trigger particles in at least
	
a flexible polymer outer membrane encapsulating the 	 one of the one or more liquid phases in contact with
	
liquids, the polymer outer membrane having a melt-	 the polymer outer membrane, wherein the one or
ing temperature; and	 more energy absorbing trigger particles sediment in
	
one or more energy absorbing trigger particles contained 20	 the at least one of the one or more liquid phases in
	
in at least one of the liquids in contact with the poly- 	 contact with the polymer outer membrane, and
	
mer outer membrane, wherein the one or more energy 	 wherein at least one of the one or more energy absorb-
	
absorbing trigger particles are co-encapsulated with
	
ing trigger particles is in contact with the polymer
	
the liquids by the flexible polymer outer membrane,	 outer membrane, wherein the one or more energy
	
wherein the one or more energy absorbing trigger 25	 absorbing trigger particles have a higher specific
	
particles sediment in the at least one of the liquids in 	 absorption rate for radiofrequency, microwave, or
	
contact with the polymer outer membrane, wherein at	 ultrasound energy than the specific absorption rate of
	
least one of the one or more energy absorbing trigger	 the polymer membrane, and wherein the temperature
	
particles are in contact with the polymer outer mem-	 of the one or more energy absorbing components is
	
brane, wherein the one or more energy absorbing 30	 increased by absorbing the energy to melt at least a
	
trigger particles have a higher specific absorption rate 	 portion of the polymer outer membrane;
	
for radiofrequency, microwave, or ultrasound energy 	 delivering the one or more microcapsules in tissue; and
	
than the specific absorption rate of the polymer outer 	 applying the radiofrequency, microwave, or ultrasound
	
membrane, and wherein the temperature of the one or	 energy to the one or more microcapsules such that at
	
more energy absorbing trigger particles is increased 35	 least one of the one or more energy absorbing trigger
	
by absorbing the energy to melt at least a portion of 	 particles in at least one of the one or more microcapsules
the polymer outer membrane; 	 increases in temperature by absorbing the energy
delivering the one or more microcapsules in tissue; and	 thereby melting the respective polymer outer membrane
	
applying the radiofrequency, microwave, or ultrasound 	 of the at least one of the one or more microcapsules and
	
energy to the one or more microcapsules such that at 40	 thereby releasing the encapsulated immiscible liquids.
	
least one of the one or more energy absorbing trigger 	 14. A method of controlling the release of one or more
	
particles in at least one of the one or more microcapsules 	 immiscible liquids comprising the steps of:
	
increases in temperature by absorbing the energy	 providing one or more microcapsules wherein the one or
	
thereby melting the respective polymer outer membrane 	 more microcapsules comprise:
	
of the at least one of the one or more microcapsules and 45	 one or more immiscible liquids;
	
thereby releasing the encapsulated immiscible liquids.	 a flexible polymer outer membrane encapsulating the
2. The method of claim 1, wherein the polymer outer mem-	 liquids, the polymer outer membrane having a melt-
	
brane comprises polyvinyl alcohol and the one or more 	 ing temperature; and
	
energy absorbing trigger particles comprises aluminum pow- 	 one or more energy absorbing trigger particles contain-
der.	 50	 ing a radiocontrast media, wherein the one or more
3. The method of claim 1, wherein the microcapsule has a 	 energy absorbing trigger particles are contained in at
diameter of from about 1 to about 500 microns.	 least one of the one or more liquids in contact with the
4. The method of claim 1, wherein the microcapsule has a 	 polymer outer membrane, wherein the one or more
diameter of from about 300 to about 500 microns.	 energy absorbing trigger particles sediment in the at
5. The method of claim 1, wherein the microcapsule has a 55	 least one of the one or more liquids in contact with the
diameter of from about 50 to about 300 microns.	 polymer outer membrane, and wherein at least one of
6. The method of claim 1, wherein the microcapsule has a 	 the one or more energy absorbing trigger particles is
diameter of from about 30 to about 50 microns.	 in contact with the polymer outer membrane, wherein
7. The method of claim 1, wherein the microcapsule has a 	 the one or more energy absorbing trigger particles
diameter of from about 20 to about 30 microns.	 60	 have a higher specific absorption rate for radiofre-
8. The method of claim, wherein the microcapsule has a 	 quency, microwave, or ultrasound energy than the
diameter of from about 1 to about 20 microns.	 specific absorption rate of the polymer outer mem-
9. The method of claim 1, wherein the one or more micro-	 brane, and wherein the temperature of the one or more
	
capsules are contained in a pharmaceutically acceptable solu- 	 energy absorbing trigger particles is increased by
tion.	 65	 absorbing the energy to melt at least a portion of the
10. The method of claim 1, wherein all mixing between the 	 polymer outer membrane;
immiscible liquids is substantially limited. 	 delivering the one or more microcapsules in tissue; and
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applying the radiofrequency, microwave, or ultrasound
energy to the one or more microcapsules such that at
least one of the one or more energy absorbing trigger
particles in at least one of the one or more microcapsules
increases in temperature by absorbing the energy
thereby melting the respective polymer outer membrane
of the at least one of the one or more microcapsules and
thereby releasing the encapsulated one or more immis-
cible liquids.
15. The method of claim 14, wherein the radiocontrast
media is a halogenated oil, wherein the one or more energy
absorbing trigger particles comprises aluminum powder, and
wherein the flexible polymer outer membrane comprises
polymer alcohol.
16. The method of claim 15 wherein the halogenated oil is
poppy seed oil, cotton seed oil, soybean oil, safflower oil, corn
oil, sunflower seed oil, sesame seed oil, or canola oil.
17. The method of claim 15, wherein the halogenated oil is
iodinated poppy seed oil.
18. A method of controlling the release of two to four
immiscible liquid phases comprising the steps of:
providing one or more microcapsules wherein the one or
more microcapsules comprise:
the two to four immiscible liquid phases;
a flexible polymer outer membrane encapsulating the
liquid phases, the polymer outer membrane having a
melting temperature;
44
an energy absorbing trigger particle in a liquid phase in
contact with the polymer outer membrane; and
a drug, in a liquid phase not in contact with the polymer
outer membrane;
5	 delivering the one or more microcapsules in tissue; and
applying radiofrequency, microwave, or ultrasound energy
to the one or more microcapsules such that at least one of
the one or more energy absorbing trigger particles in at
least one of the one or more microcapsules increases in
10 temperature by absorbing the energy thereby melting the
respective polymer outer membrane of the at least one of
the one or more microcapsules and thereby releasing the
encapsulated one or more immiscible liquids;
wherein the energy absorbing trigger particle sediments in the
15 liquid phase in contact with the polymer outer membrane,
wherein the energy absorbing trigger particle is in contact
with the polymer outer membrane, and
wherein the energy absorbing trigger particle has a higher
specific absorption rate for the radiofrequency, microwave, or
20 ultrasound energy than the specific absorption rate of the
polymer outer membrane.
19. The method of claim 18, wherein the flexible polymer
membrane comprises polymer alcohol and the one or more
energy absorbing trigger particles comprises aluminum pow-
25 der.
